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The correlation between allergic disease and viral infections has been well established. 
While respiratory viral infections are strongly correlated with the development of 
allergic asthma, it is not known precisely how viral infection may produce, or 
alternatively protect, against allergic disease. Furthermore, little is known about the 
impact of viral infection on IgE sensitisation, due to conflicting and limited research. 
Recently, neutrophil extracellular traps (NETs) have been observed in viral infections 
and shown to induce a Th2 response. We aim to explore the link between virus infection 
and allergy and test if the link is mediated through NETs. We hypothesise that NETs are 
induced during viral respiratory infections, but that they do not adequately control the 
viral disease. Instead, they contribute to the development of allergic disease, and their 
removal will be beneficial to patients. 
 
This hypothesis was addressed by sensitising rats to ovalbumin (OVA), during a 
respiratory viral infection and re-exposing the animals to OVA one week after 
sensitisation. To test the involvement of NETs, DNase-I was administered during viral 
infection to degrade NETs. OVA-specific IgE serum levels, along with cellular infiltrates 
into the airways, were compared between groups to assess allergic sensitisation before 
and after OVA re-exposure. 
 
Although no effect on IgE sensitisation was observed with viral infection, DNase 
treatment reduced the risk of IgE sensitisation and increased T regulatory cell (Treg) 
proportions in the airways, which also displayed higher levels of FoxP3. We did not 
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observe a difference between any of the groups in respect to allergic recall response 
suggesting that the achieved sensitisation was not sufficient to induce clinical disease. 
Our findings nevertheless suggest that DNase treatment induces a regulatory response, 
which may protect against allergic disease.  Future studies should explore this 
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There is a well-established link between respiratory viral infections and allergic disease. 
In particular, respiratory viral infections are strongly correlated with the development 
of allergic asthma, but it is not well known how infection alters the processes involved 
in IgE sensitisation. More recently, neutrophil extracellular traps (NETs) have been 
observed in viral infections and shown to induce Th2 immune cells, which are crucial to 
allergy development. These findings may explain the link between viral infection and 
allergic disease. The following review aims to collate the research surrounding virus and 
allergy development, with a focus on the role of neutrophil extracellular traps, or 
extracellular DNA, produced during respiratory viral infections. 
 
1.2. Respiratory system  
Every single minute a healthy human inhales 6 litres of air (1). This air contains the 
oxygen your body requires to carry out vital life processes, including the conversion of 
food into energy (respiration). The conducting portion of the respiratory system, 
including the nasal cavity, pharynx, larynx, trachea, bronchi and bronchioles, create a 
continuous passageway towards the respiratory zone. While in this conducting section, 
air is warmed, humidified and partially cleansed of particle matter, to protect the 
delicate respiratory tissues. The air then continues through a series of smaller and 
smaller bronchioles, until it reaches the respiratory bronchioles, and finally the alveoli. 
These alveoli have incredibly thin respiratory membranes, designed to facilitate gas 




Given that 6 litres of air pass through the lungs each minute, or approximately 9000 
litres per day, the lungs are constantly exposed to a vast array of microbes, allergens 
and particulate matter. To combat these pathogens, both innate and adaptive immune 
cells are present in the respiratory system. The innate system provides rapid, first-line 
defence against pathogens and is present from birth. Natural barriers, such as epithelial 
and mucus layers, are components of this system. Immune cells, such as macrophages, 
granulocytes, dendritic cells (DCs) and natural killer (NK) cells are also part of the innate 
immune system and will be discussed in more detail later. Cells from this leg of the 
immune system initiate their defence roles through pattern recognition. They respond 
to microbial structures termed pathogen-associated molecular patterns (PAMPs), via 
pattern recognition receptors (PRRs). The innate response is incredibly rapid (minutes 
to hours) but is somewhat inefficient and unspecific when compared to the adaptive 
system. The adaptive system is triggered by cells of the innate system and takes days or 
weeks to develop. However, the benefit of the adaptive system is that protection is 
more efficient and long-lived, due to the production of clonally expanded, highly specific 
lymphocytes and soluble immunoglobulins (Ig), that reside in the bone marrow and 
affected tissues for up to several years (3). 
 
The difficult job for the respiratory immune system is to distinguish the large amounts 
of highly immunogenic, but predominately harmless antigens, from the small amounts 
of pathogens requiring efficient clearance.  If every single antigen presented evoked a 
strong, adaptive immune response, the detrimental effects from chronic airway 
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inflammation would be devastating (4). Hence, the immune system in the airways must 
be tightly controlled and regulated, to prevent and repair associated tissue damage.  
 
This tightly controlled regulation occurs as a series of tiered, inter-related pathways, 
with multiple feedback and inhibition pathways. In general, signals are recognised by 
sensor cells, which can then exhibit direct pathogen clearance, directly recruit 
neighbouring effector cells, or trigger a tiered, cascade of intracellular events. Multiple 
innate immune cells can act as sensor cells, including epithelial cells, macrophages, DCs 
and mast cells.  There is also a multitude of effector responses that may occur, involving 
both innate and adaptive responses (5). Due to the complexity of the potential immune 
responses possible in the respiratory system, the following sections will focus on how 
particular cell types change from steady state functions during a viral infection.  
 
1.3. Innate immunity in the respiratory system 
1.3.1. Epithelial cell barrier functions 
The airway epithelial cells line the airways to provide a chemical, physical, and 
immunological barrier, as well as allowing for gas exchange in the respiratory regions.  
The epithelium acts as a barrier between the external and internal environment, by 
three general mechanisms. Firstly, the polarised epithelium is selectively permeable to 
ions and macromolecules, through receptors, transporters and tight junctions. In normal 
epithelial tissues, cell-cell junctions, namely intracellular tight junctions, prevent inhaled 
pathogens from entering and injuring the airways. Secondly, antimicrobial secretions, 
such as host defence proteins, help to destroy inhaled pathogens. Thirdly, the 
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mucociliary escalator acts to trap and remove inhaled particle matter from the airways.  
(1, 5-9).  
 
The upper portion of the conducting region is lined with pseudostratified epithelium; 
including ciliated, secretory and basal cells. Most cells in the conducting region are 
ciliated cells (over 50%), with approximately 200-300 cilia on its luminal surface. 
Immediately below these cilia are many mitochondria, which provide energy for ciliary 
beating. The other main cell type present in the conducting regions are secretory cells, 
which secrete mucus components into the airways. Mucus functions to trap inhaled 
particles and pathogens and prevent damage to the respiratory membranes. This mucus 
is then beaten away from the respiratory zones, up towards the pharynx, by cilia. Mucus 
production is highly regulated, as over-production may block the airways and impair 
mucociliary clearance, while under-production could allow foreign particles to damage 
the delicate respiratory tissues (1, 10, 11).  
 
Along with this mucociliary escalator, the epithelium prevents pathogen invasion 
through antimicrobial secretions. Epithelial cells secrete an array of products into the 
airway lumen to destroy inhaled pathogens. Enzymes, protease inhibitors, oxidants, and 
antimicrobial peptides are a few examples of such substances (1, 9).  
 
1.3.2. Epithelium during inflammation/ diseased epithelium 
The early response to a respiratory infection can cascade down many different, inter-
related pathways. Generally, these can be described as direct pathogen clearance, a 
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direct effector cell response or a multi-tiered, multi-cellular response (5). The epithelium 
houses an array of resident immune cells, including DCs, macrophages, and some T and 
B cells (12) which act to sense and elicit responses to pathogen signals.  
 
Along with barrier functions described above, epithelial cells also help to recognise 
pathogens by expressing pathogen recognition receptors (PRRs). They can then trigger 
an immune response through the release of an array of mediators, including; thymic 
stromal lymphopoietin (TSLP), interleukin (IL)-1b, IL-4, IL-3, IL-6, IL-25, IL-33, CXCL8, GM-
CSF, and thus act to dictate the initial response to infectious stimuli by the respiratory, 
immune system (6, 9, 13, 14). 
 
The subsequent response to infectious stimuli is responsible for efficiently clearing 
sensed pathogens. However, it is critical that proinflammatory signals are tightly 
controlled, as excessive inflammation can very quickly lead to detrimental effects. 
Hence, regulator components are a crucial part of the immune response (9). During the 
steady state, airway epithelial cells secrete regulatory cytokines, such as IL-10, to 
prevent the activation of resident immune cells. Disruption of this regulation, such as 
during a viral infection, indicates that the epithelial barrier has been damaged and acts 
as an activation signal for downstream anti-viral events (15). 
 
During inflammation host factors, such as interferons (IFN) and transforming necrosis 
factor alpha (TNF-α), can disrupt tight junctions between epithelial cells, increasing 
permeability for immune cell infiltration. However, persistantly increased permeability 
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can allow unwanted allergens and pathogens passage through the epithelium. This can 
then further disrupt barrier functions and result in disrupted epithelial differentiation 
and repair processes. Downregulation of E-cadherin can lead to degradation of tight 
junctions, increasing allergen access to submucosal regions, stimulating a Th2 mediated 
response (6, 8, 14).  
 
Furthermore, during airway inflammation, mucus production is often increased. 
Inflammatory mediators, such as TNF-α, IL-9, IL-13 and neutrophil elastase, as well as 
growth factors, allergens and microbe products, can stimulate mucus hypersecretion (1, 
16-20). In addition to obstructing the airways, defective mucociliary clearance can result 
in recurrent and persistent respiratory infections, when pathogens fail to be cleared 
from the airways (1). This is evident in cystic fibrosis and common obstructive pulmonary 
disorder (COPD) patients (21, 22) Persistent infections then further drive the system 
away from homeostasis, by promoting an inflammatory response, which may further 
damage the epithelial layer (1).  
 
1.3.3. Macrophages and dendritic cells  
To allow for efficient clearing of potentially harmful microbes, the respiratory system 
houses many local immune cells capable of rapidly responding to the invading 
microorganism. Arguably one of the most important of these cells are alveolar 
macrophages and DCs. Alveolar macrophages travel round the airway spaces, while 
resident DCs are localised to the epithelial layer, with protrusions reaching into the 
airways to sample passing antigen. During inflammation, these cells can directly clear 
sensed pathogens via phagocytosis, produce cytokines to rapidly recruit effector cells, 
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or process and present antigens to the adaptive immune system. Importantly, this 
includes the ability to present antigen to antigen-specific memory CD4+ T cells in the 
lung and lymph nodes, allowing for more rapid adaptive responses. They also play an 
important role in the steady-state clearing of cellular debris and preventing aberrant 
inflammation (3, 15). 
 
1.3.3.1. Macrophages 
Resident tissue macrophages are believed to be derived from monocytes circulating in 
the blood and from GM-CSF induced local precursor proliferation. Alveolar macrophages 
are long-lived cells, with a turnover of approximately 40% in a year. They can display a 
high degree of heterogeneity, both between and within tissues (15, 23). Alveolar 
macrophages produce immunosuppressive prostaglandins and TGF-β, which suppress T 
cell activation. They may also enhance Treg development, by secreting TGF- β and 
retinoic acid (15). 
 
Resident tissue macrophages can be broadly categorised into pro-
inflammatory/classically activated (M1) and anti-inflammatory/alternatively activated 
(M2) macrophages. M1 macrophages appear to be IL-4 producing, while M2 appear to 
produce IL-13. There is a great deal of debate surrounding whether macrophages in 
healthy lung tissue are M1 or M2 in nature (15, 24).  
 
In the steady state, epithelial cells produce cytokines and cell receptors to negatively 
regulate alveolar macrophages, such as IL-10, TGF-β and CD200. During the steady state, 
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these macrophages remain inactivated and mainly function to clear dead cells and 
debris by phagocytosis. They are quite poor at presenting antigen and have decreased 
phagocytotic activity, although they are capable of transporting antigen to airway 
draining lymph nodes (ADLNs). They also produce regulatory cytokines themselves, such 
as TGF-β, which acts to suppress T cell activation (15). 
 
A lack of these inhibitory signals, due to disrupted epithelial cell function, results in 
macrophage activation. Macrophages can also be directly activated by other activation 
signals. Examples of these include PAMPs binding to PRRs, or inflammatory cytokines 
(TNF, IL-1b) binding to their receptors. Activated macrophages have greater 
phagocytotic ability, become better at presenting antigen, and produce high amounts 
of inflammatory cytokines (15). Furthermore, pro-inflammatory conditions in the 
airways can result in recruitment of inflammatory monocytes, (or CCR2+Ly6C+ 
monocytes) which can then differentiate into macrophages (24). These recruited 
monocytes produce cytokines, such as type I IFNs, TNF and IL-6, which further enhance 
the recruitment of inflammatory cells (15)  
 
1.3.3.2. Dendritic cells  
DCs have the important role of continually “surveying” antigen-exposed sites and 
deciding on an immunogenic or tolerant response. Even in the steady state, DCs/ 
monocyte precursors are constantly transporting antigen to ADLNs and recruited back 
to the tissue (25). Failure to decide on the correct response could delay the 




Steady state, sentient DCs are unable to effectively present antigen to T cells, despite 
constantly migrating to ADLNs. However, co-exposure to antigens with PAMPs/danger-
associated molecular patterns (DAMPs) results in DC activation. DCs then migrate to 
ADLNs to interact with T cells, where they play an important role in T cell activation (26) 
(see adaptive immune section). 
 
Following activation, DCs display large amounts of processed antigen with MHC cell 
surface molecules, in conjunction with T cell co-stimulatory factors locally in the airways, 
where they activate memory lymphocytes.  In this state, DCs are stronger T cell 
stimulators than other antigen presenting cells, including macrophages and B cells. 
Furthermore, inflammatory signals result in a rapid increase in pro-inflammatory DC 
recruitment, further driving the inflammatory process. (26). 
 
Dendritic cells can be subdivided into plasmacytoid DCs (pDCs) and conventional DCs 
(cDCs). Broadly, pDCs are important for their early response to viral infections, due to 
their ability to produce large amounts of IFN-α/β.  In rats, pDCs can be classified by their 
expression of MHC class II, CD172 expression and lack of CD11b and CD103 expression. 
Conventional DCs also express MHC class II, but at a lower level than pDCs. Conventional 
DCs further express CD11b with varied expression of CD103, CD172 and CD4. Both are 
found in steady-state airways, however, pDCs make up a very small proportion of the 





1.3.4.1. Granulocyte recruitment 
Granulocytes are not typically found within the alveolar spaces in the steady state; 
instead, they are rapidly recruited to the tissue in response to inflammatory signals, 
predominantly expressed by epithelial cells.  
 
Granulocyte recruitment begins with changes to the endothelium, due to inflammatory 
mediators. Endothelial cells increase expression of cellular adhesion molecules, such as 
P-selectin and E-selectin. These selectins then bind to their ligands and work to tether 
free-flowing neutrophils on the endothelial surface. Similarly, eosinophils are drawn to 
endothelial cells by multiple chemoattractant molecules (such as IL-5, IL-13, GM-CSF and 
RANTES), and bind to the endothelial surface via cell adhesion molecules. Granulocytes 
then roll along the endothelial surface via these adhesion molecules, in the direction of 
blood flow. While rolling, granulocytes are exposed to several chemokines needed to 
induce activation. CXCL8, CXCL1, CXCL2 and CXCL5 are important examples of these. The 
granulocyte then adheres to the endothelial surface and begins to crawl towards a 
chemical gradient. They then transmigrate out from the blood vessel, either travelling 
paracellularly or transcellularly. Paracellular transmigration occurs most frequently, at 
endothelial cell-cell junctions (28-30). 
 
1.3.4.2. Neutrophils  
Once neutrophils have reached their recruitment site, neutrophils have several effector 
functions to aid in eliminating the threat. They are most commonly known for their 
efficient phagocytosis, where infected cells are engulfed and destroyed by reactive 
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oxygen species (ROS). Neutrophils also degranulate to release toxic granule proteins, 
such as myeloperoxidase (MPO), elastase and defensins (31). Finally, they can release a 
net-like structure composed of chromatin and granule proteins to entrap and destroy 
pathogens (3, 32). 
 
1.3.4.2.1. Neutrophil extracellular traps 
Neutrophils are capable of releasing a net-like structure composed of chromatin and 
granule proteins, thought to assist in defence by entrapping and destroying pathogens 
(32). Since the discovery of these neutrophil extracellular traps (NETs) in 2004, they have 
been explored in bacterial, fungal and viral infection studies (33-36). There seems to be 
no single trigger that leads to their formation, but rather a wide variety of signals. TLR-
ligands, complement, and activated platelets are examples of these (37). Viral particles 
can also trigger their formation via PRR, as can secondary signals from infected cells, 
such as GM-CSF (38). This ability to be induced via secondary signals may be particularly 
useful in viral infections, by allowing the immune system to recognise virus that may 
otherwise remain “hidden” inside infected host cells. It also aids in recognition of 
multiple, changing viral surface particles. 
 
NET formation appears to be related to the production of reactive oxygen species (ROS) 
by NADPH oxidase, as disruption of this system prevents their formation (34, 39). The 
production of ROS by NADPH oxidase leads to the breakdown of granule membranes, 
and the granule contents are translocated to the nucleus. Peptidyl arginine deiminase 
(PAD4) and elastase trigger histone modifications, causing chromatin de-condensation. 
PAD4 appears to be another essential part of the NETosis pathway, as PAD4 deficient 
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mice are unable to produce NETs (40). The nuclear membrane then breaks down, and 
granule proteins associate which DNA. Finally, the plasma membrane bursts, leaking the 
contents into the extracellular space  (41). This process is distinctly different from other 
forms of cell death (34) and may not always involve the death of the cell (42, 43). 
 
1.3.4.3. Eosinophils  
Eosinophils can be recruited by many interacting molecules and pathways, including 
C5a, platelet-activating factor, IL-2, IL-3, IL-5 and GM-CSF, many of which are released 
by epithelial cells. They are involved in defence against helminths and play a role in 
allergic disease. In response to mediators, such as histamine, they degranulate to 
release ROS, cytokines, enzymes, growth factors and granule proteins (3, 29). An 
increased number of eosinophils in the blood (eosinophilia) is a clinical marker for many 
diseases. In allergic pathologies, eosinophil titres often correlate with severity (44, 45). 
Excessive numbers of eosinophils can lead to tissue damage from cytotoxic granule 
proteins.  
 
1.3.5. Other innate cells 
Innate lymphoid cells (ILCs), are lymphoid- like cells that assist with regulating tissue 
homeostasis and inflammation. Group 1 ILC lineage includes cells that produce type one 
cytokines, most notably interferon gamma (IFN- γ) and tumour necrosis factor (TNF) 
NK cells are a component of this group.(46, 47) NK cells recognise cells lacking MHC 
class I and cause cell death. They play a role in the early viral response, prior to CD8+ T 
cell activation and expansion (see adaptive section). Group 2 ILCs produce IL-5 and IL-
13. They are thought to contribute to allergic pathologies, by producing these Th2 type 
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cytokines.(46) Furthermore, group 2 ILC populations may increase in allergic asthma 
models (47, 48). A third group of ILCs has also been defined, that are dependent on 
RORγ, and secrete IL-12 and IL-22 (46, 47).  
 
1.4. Adaptive immunity in the respiratory system 
In the steady state, to limit excessive inflammation, only a small number of adaptive 
immune cells are present in the lungs, namely tissue-resident memory T cells and 
regulatory T cells. Below, describes the processes of lymphocyte activation and the 
different subtypes involved in an inflammatory or regulatory response.  
 
Lymphocytes are produced in the thymus and bone marrow. During development, 
selection and re-combination processes yield immature lymphocytes, capable of 
responding to antigens. During selection, the majority of cells which respond to self-
antigen are destroyed or inactivated, yet, a small number escape this process, giving rise 
to autoimmune disorders (3). 
 
1.4.1. T cell activation  
T cells are unable to bind to antigen directly, instead, they respond to MHC bound 
antigen peptides, displayed by antigen presenting cells. To recognise these antigen 
peptides, T cells express antigen-specific T cell receptors (TCRs), in a complex with CD3. 
CD3 is a signal transduction molecule and plays an important role in the early phases of 
T cell activation. The interaction between the MHC bound antigen peptide on the 
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antigen presenting cell, and the TCR-CD3 complex (TCR complex) expressed on the T 
cell, is the first signal required for T cell activation (Figure 1.1) (3). 
 
TCRs are also expressed in association with CD4 or CD8 co-receptors. The CD4 or CD8 
co-receptor is involved in the first activation signal (Figure 1.1.). CD4 binds with MHC 
class II bound on APCs and in general, used to present extracellular antigens, while CD8 
binds with MHC I, expressed on all nucleated cells, including APCs and in general used 
to present intracellular antigens. Expression of CD4 or CD8 distinguishes T cells into two 
subset populations; CD4+ and CD8+ T cells (3).  
 
T cell activation also requires co-stimulatory pairs, to enhance the signal delivered to 
the TCR complex (Figure 1.1.). There is an extensive number of such co-stimulatory pairs, 
such as B7 with CD28, CD40 with CD40L, and ICAM-1 with LFA-1 (3, 49). 
 
Adhesion molecules also assist in T cell activation, by slowing the movement of T cells 
near APCs, allowing more time for presentation in the ADLN. Examples of such 




Figure 1.1.T cell activation by antigen presenting cells. T cell activation requires two signals; 
one is provided by antigen bound to MHC, in conjunction with a co-receptor, and the second by 
co-stimulatory pairs. Adapted from Figure 11.1, Coico R, Sunshine G. Immunology: a short 
course: John Wiley & Sons; 2015 (3).  
 
Following these initial activation signals, a series of intracellular signal cascades occur, 
transmitting the signal through the cytoplasm and into the nucleus. IL-2 and IL-2 
receptor (CD25/IL-2Rα forms part of this receptor complex) synthesis increases, leading 
to rapid T cell expansion. Towards the end of this expansion phase, activated T cells 
differentiate into effector and memory T cells (3). 
 
1.4.2. T cell effector functions 
 
As previously mentioned, T cells can be broadly categorised by their expression of CD4 
or CD8. The main function of CD4+ T cells is to produce cytokines. Hence, they are 
involved in influencing immune responses and are also often called “T helper” (Th) cells. 
CD8 T cells are predominately involved in killing infected cells and are often called “killer 




1.4.2.1. CD4+ T cells 
CD4+ T cells can then be further subdivided according to the cytokines they synthesise 
once activated. The main subsets include T regulatory (Treg) and T effector cells, which 
can further be classed as Th1 or Th2 cells. However, there is some discussion regarding 
the simplicity this categorisation implies. Response to pathogens and the subsequent 
cytokines produced are likely to have considerable overlap.  
 
1.4.2.1.1. Th1 
An increase in Th1 type cells is often seen in response to viral infection. Th1 cells develop 
in the presence of IL-12, which is produced by DCs, NK cells, and other innate cells as an 
early response to intracellular infections. Th1 cells synthesise IFN-γ and IL-12, which 
promote activation of macrophages, CD8+ T cells and NK cells (3).  
 
1.4.2.1.2. Th2 
Th2 type cells develop in the presence of helminth infections, and in response to 
allergens. Furthermore, the airways are typically more skewed towards a Th2 response 
from birth (50).Th2 cells typically synthesise IL-4, IL-5 and IL-13. IL-4 production further 
drives the production of more Th2 cells. It also induces the formation of T follicular 
helper (Tfh) which continue to produce IL-4 and IL-13. Both influence B cell class 
switching to IgE isotypes, which will be explained in more detail below. IL-5 is involved 




1.4.2.1.3. T regulatory cells 
Tregs play an important role in suppressing unwanted immune activation and limiting 
the expansion of activated lymphocytes. This is incredibly important for preventing 
excessive inflammation and autoimmune disorders. They can be categorised into 
natural Tregs (nTregs), which are involved in maintaining peripheral tolerance and 
limiting chronic inflammation, and induced Tregs (iTregs), which are recruited during 
adaptive responses to limit inflammation. Tregs predominantly exert their suppressive 
effects with TGF-β and IL-10 signalling molecules (51). 
 
An important distinguishing marker for Tregs is the transcription factor forkhead box P3 
(FoxP3), as FoxP3 has a critical role in Treg function (52). Foxp3 was first identified as a 
defective gene in Scurfy mice, who harbour a hyperactive CD4+ T cell disorder (53) 
prompting researchers to explore its role in Treg function. FoxP3 has since been shown 
to be a critical component for Treg differentiation from α/β TCR-positive T cells in the 
thymus. Transduction of Foxp3 into CD4+CD25− T cells can convert them into 
CD4+CD25+ Treg-like cells, which display immune suppressive properties (54). 
Transduction of Foxp3 into naïve T cells up-regulates some Treg cell-surface molecules, 
including CD25, and down-regulates production of IL-2, IFN-γ, and IL-4. Foxp3 deficient 
mice have fewer CD4+CD25+ Tregs. Furthermore, treating Scurfy mice with CD4+CD25+ 
Tregs from normal mice prevents CD4+ T cell-mediated inflammation (55). Foxp3 
overexpression increases the amount of CD4+CD25+ T cells, and also results in 




IL-2 is another molecule critical to Treg function. CD25 forms part of this receptor (ILRα) 
and is used as a marker for cell activation. IL-2 has multiple effects on multiple target 
cells, including aiding the differentiation and expansion of CD4+ T cells, CD8+ T cells and 
NK cells.(57, 58). IL-2 maintains FoxP3+ Treg populations, by facilitating their 
differentiation (59) or acting as a Treg growth factor (57). Evidently, CD25 deficiencies 
are associated with autoimmune and allergic disorders (60-63). 
 
Contrary to other thymic T cells, functionally mature Tregs cells can be found in the 
thymus, prior to encountering antigen in peripheral lymphatic tissues. These Tregs are 
involved in suppressing naïve T cells from recognising self-antigens (58, 64). Naïve T cells 
in the periphery are also capable of developing into Treg cells, under a number of 
stimuli, including IL-2 (59). However, the functional capabilities of these induced Tregs 
are still unclear (58). 
 
FoxP3+ Tregs specific for tissue self-antigens are found in regional lymph nodes (65) 
Tregs also display a number of receptors for homing molecules, such as CCR7, to localise 
Treg functions to particular areas (58).  
 
Following antigenic stimulation, Tregs downregulate an anti-apoptotic protein, Bcl-2 
(66). This indicates that cell death helps to maintain Treg homeostasis, much like other 
activated T cell populations. However, it still remains to be seen whether some of these 




Tregs suppress both the proliferation of naïve T cells and their differentiation into 
effector cell subtypes. They also suppress the effector functions of CD4+ T cells, CD8+ T 
cells, NK cells, B cells, macrophages and DCs. Tregs suppressive functions are believed 
to occur via cell-cell contact with DCs downregulating DC functions, sequentially 
downregulating T cell activation. (58, 67-70). 
 
1.4.2.2. CD8+ T cells 
CD8+ T cells can be activated by APCs, or by APCs and CD4+ T cells, leading to rapid 
clonal expansion. In the case of virus infection, activated CD8+ T cells attach to infected 
cells and activate apoptotic pathways. These CD8+ T cells recognise infected cells when 
they express both the viral antigen and MHC class I molecule seen during their activation 
(3, 71).  
 
1.4.3. Memory T cells 
As previously explained, activation of T cells leads to clonal expansion and antigen-
specific T cells. Following the elimination of the pathogen, most of these cells are 
eliminated. However, some of these cells survive, sometimes for years, as memory T 
cells. These memory cells allow for a more rapid and effective response if there is a re-
exposure to the specific antigen (3, 71, 72). 
 
1.4.4. B cells and antibody production  
Naïve B cells circulate through the blood to secondary lymphoid tissues, such as the 
ADLNs. Here, naïve B cells are activated by interacting with antigen and Tfh in germinal 
20 
 
centres. Once activated, B cells can differentiate into antibody-secreting plasma cells in 
the germinal centre of lymph nodes. These cells synthesise and secrete a specific 
antibody isotype, specific for a given antigen. These plasma cells also express CD27, 
which allows them to be distinguished from other B cell stages (3, 73).  
 
The potential antibody (immunoglobulin, Ig) isotypes are IgM, IgG, IgA or IgE. IgG, IgA 
and IgM are involved in anti-viral immunity, with the most important of these being IgM, 
due to its role in complement-mediated cell lysis. IgG plays a large role in opsonisation, 
and therefore facilitating the phagocytotic destruction of invading pathogens. Secretory 
IgA plays a role in preventing virions from entering host cells. IgE is associated with 
allergic disease and defence against helminths. Class switching of B cells to IgE is 
promoted by IL-4 and IL-13 cytokines (3).  
 
Plasma cell populations can survive for days to years. Long-lived plasma cells can 
differentiate into memory B cells. These cells do not proliferate but can survive for years 
in the bone marrow or affected tissue. Upon re-exposure to antigens, these memory 
cells can differentiate back into plasma cells (3, 73).  
 
1.4.5. B and T cell interactions  
Activated T- helper cells migrate to the B cell region of the ADLNs where they mediate 
B cell antigen-specific activation. This type of T cell display CXCR5 receptor on its surface 




B cells also interact with T cells as antigen presenting cells. Unlike T cells, B cells can 
capture antigen using their BCR and internalise the antigen for processing. B cells are 
then able to present the peptide with MHC class II to a CD4+ T cell with the appropriate 
TCR epitope (3).  
 
1.4.6. NKT cells 
NKT cells are a type of immune cell that express TCR, as well as typical NK cell molecules. 
There are many subtypes of this cell type, but generally, they function as immune 
regulators, and to kill cells by triggering cell death pathways. Once activated, they 
secrete IL-4 and INF-γ (3, 74). 
 
1.5. Inflammatory resolution 
Once a viral infection in under control and infected cells have been removed, recruited 
and expanded cell populations must be removed to prevent aberrant inflammation, 
which can quickly lead to excessive tissue damage. Failure to correctly harbour the 
inflammatory response can lead to chronic inflammation and fibrosis, or scar tissue 
formation. 
 
Anti-inflammatory (M2) macrophages play a critical role in this phase, by secreting anti-
inflammatory cytokines and clearing up cellular debris. Activated and recruited cells 
undergo apoptosis, primarily induced by apoptotic signals expressed by M2 
macrophages. Macrophages also release soluble mediators to stimulate fibroblasts, 
which are cells that synthesise the extracellular matrix. Stimulation of these cells is 
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important for healing tissue damage caused by inflammation, but can also lead to 
fibrosis, following chronic inflammation (75, 76). 
 
1.6. Allergy/atopy 
Although the respiratory, immune system is tightly regulated, hypersensitivity reactions 
may occur, where an exaggerated immune response is induced. Allergic reactions are 
an example of such a response, wherein the typical innocuous allergen is recognised as 
harmful, and an IgE-mediated reaction is induced (3, 77).  
 
1.6.1. Mechanisms 
Mechanistically, an allergic reaction occurs in two phases; the initial exposure or 
sensitisation phase, and the re-exposure or re-call phase, which results in disease 
symptoms. Allergies can be localised to several tissues, including the skin and gastro-




Following inhalation of the typically innocuous allergen, often when co-exposed with 
other molecules, the immune system responds as it would to a harmful pathogen. The 
allergen interacts with receptors found on sensor cells, such as those on resident DCs 
and epithelial cells. DCs, and other antigen presenting cells recruited by secreted 
cytokines migrate to ADLNs, where they present allergen to adaptive immune cells. In 
the case of allergy development, T cells differentiate into Th2 cells and secrete IL-4, IL-
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13, and IL-5 cytokines. IL-4 drives further Th2 differentiation and drives B cell class 
switching to IgE in conjunction with IL-13. Th2 cells migrate to airways, where they 
reside as memory T cells. Allergen-specific IgE circulates in the blood and binds to FCƐRI 
receptors found on mast cells and basophils in the airways. Once bound to FCƐRI, IgE 
can persist on the cell surface for weeks, leaving these cells primed to react to the 
allergen upon re-exposure (3). 
 
1.6.1.2. Recall /re-exposure 
Upon re-exposure, where the antigen is inhaled and recognised by IgE in the airways, 
cross-linking of FCƐRI occurs on mast cells. This triggers the mast cells to release pre-
formed mediators and synthesise inflammatory molecules. (Figure 1.2.). The most 
notable of these pre-formed molecules is histamine. Once released histamine binds 
rapidly to a variety of cell types via H1 and H2 receptors. On smooth muscle cells the 
binding of histamine results in constriction, and on endothelial cells binding results in 
increased vascular permeability. Histamine is also involved in increased mucus 
secretion. In the airways, this results in a narrowed airway diameter and increased 
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mucus secretion. Vascular permeability leads to increased cell and cytokine infiltration, 
increasing inflammation associated with the allergic response (3). 
 
Figure 1.2. Cross-linking of IgE bound to FCƐRI on mast cells, resulting in degranulation. 




1.6.2. Allergic airway diseases 
Allergic immune responses are commonly induced due to airway antigens, such as 
pollen and house dust mites. Major allergic diseases in the airways include; allergic 
rhinitis and allergic asthma. Allergic rhinitis, commonly known as hay fever, involves 
nasal symptoms of sneezing, itching, congestion and rhinorrhea. Symptoms involving 
the eyes, ears and throat usually accompany nasal symptoms (78). Asthma defines a 
complex, heterogeneous, inflammatory disease of the airways, broadly categorised by 
airway hyperresponsiveness to a stimulus. Symptoms include cough, wheeze, shortness 





Higher incidences of allergic disease are typically seen in developed countries. The 
highest prevalence for asthma was seen in the UK, Australia, New Zealand and Republic 
of Ireland, followed by North, Central and South America, in a 1998 international 
comparison study. The lowest rates were observed in Eastern European countries, 
Indonesia, Greece, China, Taiwan, Uzbekistan, India, and Ethiopia (80) Furthermore, as 
part of the international study of asthma and allergies in childhood (ISAAC), prevalence 
of wheeze in children surveyed ranged from 0.8% in Tibet, China to 32.6% in Wellington, 
New Zealand. Ecological, economic analyses showed a significant increase in wheeze for 
higher income countries, however, this trend was reversed for severe symptoms (81). 
 
Allergy prevalence is also increasing worldwide and has been doing so for at least the 
last 50 years. Currently, 300 million people have asthma, and this is expected to rise to 
400 million by 2025 (82). 
 
In Australia, allergy is a leading cause of chronic illness, with almost 20% of the 
population having an allergic disease (83). Allergic diseases affect individuals of all ages 
and often result in persistent, gradual health deterioration over an individuals' lifespan 





1.6.4. Development  
Due to a global disparity in allergy incidence, multiple environmental factors have been 
suggested as risk factors for allergy development. A few examples of these are described 
below.  
 
1.6.4.1 Early life infections 
The integral role of the lung microbiome was first considered in 1989 as the “hygiene 
hypothesis”, as a mechanism to explain higher rates of asthma and allergic diseases in 
developed countries (85). This hypothesis proposes that exposure to bacterial and viral 
agents induces a Th1 response which skews the system away from the Th2 responses 
involved in allergy (86). Since then, the theory has evolved, and evidence to support the 
theory have been observed in several studies involving family size and daycare 
attendance (85, 87-89). However, lower respiratory infections have also been 
repeatedly associated with increased risk of asthma development (87, 90). More recent 
studies, therefore, propose that exposure to non-pathogenic microbes could potentially 
be more useful in guiding the immune response, mediating protection from allergy (91).  
 
Most applicable to our study is the associated risk between early life infections and 
allergic disease development. For example, infant respiratory syncytial virus (RSV) 
infection has been identified as an important risk factor for asthma and allergy 




1.6.4.2. Rural vs urban 
Another theory to explain the higher prevalence of allergy in developed countries is that 
rural environments may be more protective than urban. As with early infection, there is 
conflicting evidence regarding the proposed lowered risk of atopic diseases in rural 
populations (93-96). Children reared on farms typically display lower rates of atopy, but 
this is again controversial (97, 98). One proposed mechanism for lower atopy rates with 
a farming lifestyle have involved exposure to farm milk, and an associated increase in 
immune regulatory cells Evidence for this idea was provided by a study conducted in 
2014, which found increased Treg numbers with farm milk exposure, and a correlated 
reduction in atopic sensitisation (99).  
 
A particularly interesting study was conducted in 2016, comparing Amish and Hutterite 
populations. Both these populations display similar genetics and lifestyle factors, 
however, Amish follow traditional farming practices, while Hutterites use industrialised 
farming practices. Despite the similar genetic ancestries and lifestyles, allergic 
sensitisation was 6 times lower in the Amish compared to the Hutterites, while 
endotoxin levels were almost 7 times higher. Furthermore, intranasal instillation of dust 
extracts from Amish homes, but not Hutterite homes, was found to significantly inhibit 
airway eosinophilia (100).  
 
1.6.4.3. Family history 
Family history is another strong indicator for allergic disease (101). Hence, there is likely 
a genetic component to allergic disease development. Genome-wide association studies 
have observed variances in genes associated with activation and differentiation of Th2 
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responses, as well as uncovering disease heterogeneity (102-104). However, disease 
development is much more complex than simple genetics, due to numerous gene-
environment interactions.  
 
Another factor worthy of mention involves the progression of atopic dermatitis during 
infancy to allergic rhinitis and asthma in later years. This phenomenon is termed “atopic 
march”. A recent study observed that atopic dermatitis alone was not associated with 
increased asthma risk. However, atopic dermatitis and allergic sensitisation together 
displayed strong interactive effects towards asthma (105). Together, these findings 
evidently show the increasing complexity regarding the development of allergy. 
 
1.7. Virus and allergy 
As briefly described above, there is a well-known correlation between allergic disease 
incidence/severity and viral infections. However, whether viral infections are a cause, or 
consequence of allergic disease, is still of great debate. When rates of infection are 
similar, allergically sensitised children display higher rates of viral illness (106), indicating 
that atopy may influence viral disease. However, multiple studies have indicated that 
infections may enhance allergic disease symptoms and allergy development (107, 108). 
 
Acute asthma exacerbations are often prevailed by respiratory viral infection (91, 92, 
109-114). Since the advancements in sensitive molecular technologies, viruses have 
been found in 80% of wheezing episodes in children, and 50-75% of episodes in adults 
(115). Of these, the most commonly indicated are human rhinoviruses (HRVs) and 
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respiratory syncytial viruses (RSVs). RSV and HRV infections are also the main pathogens 
responsible for acute bronchiolitis in children (116, 117), leading to childhood wheeze, 
and potentially the induction or exacerbation of asthma. While many viral respiratory 
infections are self-limiting, wheezing episodes in early life have been indicated as a 
major risk factor for later asthma diagnosis (118).  
 
This may be explained, by how infant RSV bronchiolitis has many similarities to acute 
asthma. Both exhibit symptoms of wheezing, rapid breathing and airway inflammation, 
and roughly one-third of children with initial wheezing will have recurrent wheezing 
episodes (119). Hence, severe RSV or HRV infection during infancy has been postulated 
as a cause of asthma development.  
 
Evidence for this theory is shown by how RSV infection requiring hospitalisation, 
together with a family history of asthma, increase the likelihood of allergic disease 
development (120). Furthermore, infants born prior to the winter virus season were 
found to have an increased risk of developing asthma. Those born four months prior to 
the winter virus peak were at the highest risk, being 29% more likely to develop asthma 
compared to those born 12 months before the peak (121). 
 
This risk of allergic disease with the viral disease has also been associated with non-




It has been pointed out that viral infections are unlikely to be the single cause allergy 
development, but rather a small part that adds to the likelihood of disease development. 
For example, a Perth birth cohort study found HRV wheezing to be a risk factor for 
asthma development, but only if there were signs of atopy (126). Some studies suggest 
that RSV infections are not the cause of asthma, but instead, a shared genetic disposition 
for both RSV bronchiolitis and asthma exists (127). Furthermore, it is unlikely viral 
infections are the single causative factor behind allergic disease development. 
 
Regardless, it is clear virus-induced airway inflammation leads to an increased disease 
burden. Understanding the mechanisms of this inflammation may uncover novel new 
therapies to reduce this burden.  
 
1.7.1. Proposed mechanisms of virus and allergen interactions  
 
Multiple mechanisms have been proposed to explain the mechanisms surrounding virus 
and allergen interactions. As previously explained, allergic diseases are widely accepted 
to be the result of an exaggerated Th2 immune response, while virus infections are 
predominately overcome with a Th1 response.  
 
Some studies have found an inverse relationship between FceR1 receptors on pDCs and 
virally induced IFN-α responses (128, 129). Furthermore, multiple studies have 
suggested that virally-induced IFN responses may be impaired in asthmatics and other 
atopic individuals.(128-133).  
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Both allergens and virus particles act on the epithelium to trigger innate immune 
responses. In particular, they both induce TSLP, IL-22 and IL-25, which promote innate 
lymphoid cells and suppress Tregs (113). Tregs play an important role in both virus and 
allergy responses, as they are involved in balancing immune effector responses and 
tolerogenic responses. There is some evidence that Tregs may be impaired in atopy 
(113). Treg populations expressed by atopic individuals have been shown to be less 
effective at suppressing CD4+ T cells (134). Asthmatic individuals may also have lower 
Treg proportions, as shown by a lower number of Tregs in BAL fluid from asthmatic 
children. However, reductions in Treg numbers appear to be resolved with inhaled-
corticosteroid treatment (135). Furthermore, early RSV infection has been shown to 
suppress Treg development, and increase allergic susceptibility, in mice (136). 
 
1.7.1.1. DNA/NET-associated mechanisms 
Recently, chromatin released from apoptosis and necrosis of virally infected and 
responding immune cells were reported to skew the immune system towards an allergic 
Th2 response (137, 138). Additionally, with a similar mechanism, NET released from 
neutrophils during viral infections may be influencing the immune response.  
 
NETs have been shown to enhance pathogenesis numerous times, bringing into 
question the effectiveness of their defence. Extracellular DNA, and the associated 
granule proteins found in NETs are both cytotoxic, allowing them to easily harm the 
surrounding tissue (138, 139). NETs directly contribute to epithelial and endothelial cell 
death in a concentration-dependent manner (140). Interestingly, this cytotoxic effect 
was unable to be resolved with DNA digestion using DNase. Similarly, treatment with 
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elastase inhibitors failed to reduce NET-associated cytotoxicity (140). The role of 
histamine in contributing to this cytotoxicity was examined by incubating epithelial and 
endothelial cells with histones. Histones were found to prevent cell growth and 
aggravate cytotoxicity in a concentration-dependent manner (140). Another study 
reported histones contribute to endothelial dysfunction, organ failure and death during 
sepsis (141). This alludes to the cytotoxic effects of extracellular DNA, regardless of 
whether this DNA was released via NETosis.  
 
Furthermore, the possible use of NETs in assisting with pathogen clearance has been 
questioned. PAD4 deficient mice are incapable of forming NETs, and yet they still 
maintain immunity against influenza infection (142). It has been argued that while quite 
effective at ensnaring microbes, the killing ability of NETs is much less effective. 
Degradation of NETs with DNase was shown to release live bacteria, and NET formation 
seemed to interfere with phagocytotic killing, rather than aid (143). Together, these 
findings suggest NETs may not provide useful defence against virus infections and 
instead contribute to tissue damage by fueling Th2 inflammation. 
 
Last year, Toussaint and colleagues indeed showed that rhinovirus infection induces NET 
release in the airways of mice and that this release is related to Th2 cytokine induction, 
and asthma severity. Furthermore, they found exogenous DNase treatment prevented 
asthma exacerbation (144). Toussaint proposed that DNA and associated peptides from 
NETs promotes macrophage/DC recruitment during allergen challenge, driving the Th2 
response (144). Furthermore, antimicrobial peptides associated with NETs may also 
promote a Th2 response. Toussaint investigated this by inhibiting neutrophil elastase 
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and found viral-induced airway hyperresponsiveness could be reduced, indicating 
neutrophil elastase may contribute to disease (144). However, little is known regarding 
if NETs are involved in the initial allergy sensitisation process. 
 
1.7.2. Animal models  
To investigate the underlying processes involved in allergic disease development, both 
human and animal models are used. Murine models are particularly useful, as several 
factors associated with allergic airway disease can be induced. These include airway 
inflammation, airway hyperresponsiveness, and mucus production.  
 
Typical murine models of allergic sensitisation involve sensitising naïve animals to a 
protein, in conjunction with an adjuvant. Th2-high strains are preferred for this model, 
such as Brown Norway (BN) rats or Balb/C mice (27, 145, 146). Most models utilise the 
egg-white protein ovalbumin (OVA), often in combination with an aluminium hydroxide 
adjuvant (Alum), as this induces a strong Th2 dominated response. In an acute model of 
airway inflammation, animals are injected with an OVA/Alum solution intraperitoneally 
on days 0 and 14. They are then challenged with OVA on days 28-30 by nebulization with 
a 1% OVA solution. Inhaled exposure to OVA should occur for at least 20 minutes during 
these exposures. The allergic recall response is then analysed during the following 48 
hours from the last challenge. This model depends on systemic sensitisation towards 





Strickland and colleagues have developed a murine model which mimics many features 
of chronic atopic asthma, including airway hyperresponsiveness. The BN rat strain is 
used, as they are hypersusceptible to allergic airway disease, due to their Th2-high 
inflammatory profile. OVA/Alum intraperitoneal injection is used to establish 
sensitisation. Challenge occurs via 1% OVA inhalation over 60 minutes (27). In the same 
model of allergic sensitisation, virus infection has been shown to induce an exaggerated 
airway response (147). Recently, intranasal sensitisation was also achieved in the same 
model following 4 consecutive intranasals of OVA. Challenge was achieved with another 
OVA intranasal one week later (148). This model is more suitable than traditional 
OVA/Alum methods, as removal of the Alum adjuvant allows for subtle differences in 
IgE sensitisation to be assessed.  
 
1.8. Hypothesis, aims and significance of the study 
Overall, genetics and environmental factors play essential roles in allergic disease 
development. Atopic individuals that are exposed to viral infections, often develop 
atopic diseases, such as allergic asthma. While there is an established link between virus 
infection and allergy development, it remains to be understood if/how viral infection 
alters the immune processes involved in allergen sensitisation. Viral infection appears 
to drive NET formation, and NETs appear to contribute to a Th2 response in sensitised 
individuals. However, it is not known if NETs contribute to the initial allergy sensitisation 
process. 
 
We hypothesise that NETs are induced during viral respiratory infections and contribute 




To address this hypothesis, we aim to determine the role that virus infection, and 
subsequent induction of NETs/ extracellular DNA released from dying cells, plays in the 
development of allergic disease, in an allergically sensitised model.  
 
Our first aim will be to determine the role of virus infection in allergy sensitisation and 
the subsequent role of NETs/extracellular DNA. Our second aim will be to determine if 
a viral infection, and NET/extracellular DNA induction during sensitisation, alters the 
allergic recall response.  
 
To address this, male adult Brown Norway (BN) rats will be infected with an attenuated 
mengovirus, which establishes a mild respiratory infection, similar to rhinovirus 
infection in humans (125). During the infection, rats will also be exposed to ovalbumin 
(OVA), as a non-pathologic model allergen, daily over four days to establish OVA-specific 
IgE sensitisation. Rats will then be re-exposed to OVA a week later, to induce an allergic 
recall response. To then test the involvement of NETs during the sensitisation process, 
DNase-I, which degrades extracellular DNA, will be administered and compared to 
untreated controls.  
 
Our first aim will be addressed by comparing levels of OVA IgE as well as baseline 
immune profiles of allergically sensitised animals with and without the presence of a 
respiratory viral infection. Our second aim will be addressed, by analysing the allergic 
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recall response. The allergic recall response between treatment groups will be analysed 
by comparing any differences between pre- and post- OVA re-challenge.  
 
We expect that virus infection will increase the level of allergic sensitisation, as 
determined by OVA IgE titres, and that NET degradation, with DNase treatment, will 
counteract this effect. We also expect that the increased sensitisation following viral 
infection, will increase the magnitude of the allergic recall response as determined by 
airway immune cell infiltration and that NET degradation will again reverse this effect. 
This project will determine if DNase treatment during viral infection could reduce the 
risk of allergy development, without affecting the outcome of viral infection. If this can 
be achieved, DNase could prove a promising new drug candidate for the reduction of 
allergic disease development, as a consequence of respiratory viral infections. This may 




2. MATERIALS AND METHODS. 
 
2.1. Buffers and solutions 
 
2.1.1. Glucose phosphate buffer (GKN) 
Reagents (Table 2.1.) were dissolved and made up to 5 L in a volumetric flask with Baxter 
water. The solution was filter sterilised into ten 500 ml flasks and kept at room 
temperature.  
 
Table 2.1. GKN reagents. 
Reagents Concentrations  
Sodium chloride (NaCl) (Sigma) 0.14 M 
Potassium chloride (KCl) (Amresco) 5.37 mM 
Disodium hydrogen phosphate dodecahydrate 
Na2HPO4.12H2O (Amresco) 
9.94 mM 
Sodium dihydrogen phosphate dihydrate NaH2PO4.2H2O 
(Amresco) 
5 mM 
D-Glucose (Sigma) 11.1 mM 
 
 
2.1.2. Phosphate buffered saline (PBS) 
Reagents (Table 2.2.) were dissolved and made up to 5 L in a volumetric flask with Baxter 




Table 2.2. PBS reagents. 
Reagents Concentrations  
Sodium chloride (NaCl) (Sigma) 0.15 M 
Potassium chloride (KCl) (Amresco) 2.68 mM 
Disodium hydrogen phosphate (Na2HPO4) (Amresco) 8.1 mM 
Potassium dihydrogen phosphate (KH2PO4) 1.47 mM 
HCL (Sigma) 0.4 mM 
 
 
2.1.3. Heat inactivated fetal calf serum (FCS) 
FCS (Serana, Bunbury, WA, Australia, 8050512FBS) was heat inactivated by incubating 
at 56 C for 30 minutes. This was then stored in 10 ml aliquots at -20 C. When required, 
FCS was left to thaw at room temperature. FCS was then added to GKN at 5-10% as 
required. 
 
2.1.4. Bovine serum albumin (BSA) 
Bovine serum albumin (Bovagen Biologicals, VIC, Australia) was dissolved in PBS at 5% 
(BSA) and stored in 10 ml aliquots at -20 C. When required, BSA was left to thaw at 
room temperature prior to addition into appropriate buffers. Further reference to GKN 
BSA, indicates GKN with 0.1% BSA, while further reference to PBS BSA, indicates PBS 




2.1.5. Red Blood Cell Lysis  
Reagents (Table 2.3.) were dissolved in 2 L of Milli-Q water. The solution was filter 
sterilised into 500 ml flasks and kept at room temperature. The final pH of the resultant 
solution was 7.2. Both reagents were created in house.  
 
Table 2.3. Red blood cell lysis reagents.  
Reagents Concentrations 
Ammonium chloride (NH4Cl)  0.14 M 
Tris hydrogen chloride  17 mM 
 
 
2.2. Animals, allergen sensitisation and virus infection 
Male, 8-10-week-old, Brown Norway (BN) rats, bred at the Bioresources Centre of 
Telethon Kids Institute were used. All experimental protocols received prior approval by 
the Telethon Kids Institute Animal Ethics Committee (AEC #332). Animals were randomly 
assigned to experimental groups (Table 2.4.). 
 
To resemble human rhinovirus (HRV), an attenuated viral strain of mengovirus, with Poly 
(C) length 0 (vMC0) was used (125, 149, 150). Rats were inoculated intranasally with 100 
µl of 107 plaque-forming units (PFU) of vMC0. Intranasals were performed under inhaled 
isoflurane anaesthesia. Animals were weighed immediately prior to vMC0 inoculation 
for weight change monitoring. vMC0 was prepared as previously described (125) and 




vMC0 naturally infects rodents (151) and leads to a lower airway inflammatory 
response, consisting of neutrophils and lymphocytes. Due to these features, vMC0 has 









The allergen sensitisation model involved sensitising all the rats with a 100 µl intranasal 
of 1 mg/ml ovalbumin (OVA, Sigma, 9006-59-1), in a solution of sterile PBS over four 
consecutive days. Some of the virus-infected animals were also given 200 µg/ml of 
endotoxin-free deoxyribonuclease-I (DNase-I, Sigma,100265251) in conjunction with 
the OVA intranasals. Since DNase is dependent on divalent cations, PBS was 
supplemented with 5 mM of MgCl2, for all intranasals. Endotoxin-free DNase-I was 
initially dissolved to 5 mg/ml in PBS and aliquoted for storage. Aliquots were kept frozen 
at -20 C until required. Intranasals were conducted under inhaled isoflurane 
anaesthesia, and weights were recorded immediately after each intranasal for animal 
monitoring.  
 
Figure 2.1. The allergy and virus model. All animals received OVA on days 1, 2, 3 and 4. 
Viral groups were infected on day 0.5. DNase treatment groups received DNase in 
conjunction with OVA. Post-OVA re-challenge groups were challenged on day 7-11, and 




Exposure to OVA/DNase-I began 5 hours after virus infection so that initial exposure to 
the allergen (OVA) occurred during the peak of virus infection in those groups (125). To 
characterise the airway response during this regime, some samples were collected three 
days after viral infection, 24 hours after the second OVA/DNase intranasal. Some of the 
remaining animals were re-challenged 7-11 days later with 100 µl of 1 µg/ml ovalbumin- 
Texas Red (OVA-TR, ThermoFisher, 023021). So that re-challenge could be confirmed 
with flow cytometry analysis. Tissues were then collected 24 hours later. While groups 
were randomly assigned, attempts were made to include a pre and post sample for the 
chosen groups on each collection date (Figure 2.1.). 
 
Table 2.4. Animal treatment groups used for DNase treatment experiments. 
Treatment 
Group 
Number of pre-OVA 
re-challenge rats 
used 
Number of post-OVA 
re-challenge rats 
used 
Number of two-day 
exposure rats used 
OVA  6 4 3 
OVA + Virus  6 8 3 
OVA + Virus + 
DNase 
5 6 3 
 
 
2.3. Animal dissection and sample collection 
For tissue collection, rats were anaesthetised with inhaled isoflurane. Once rats were 
unresponsive, approximately 1 ml of blood was collected via cardiac puncture. This 
blood was then placed into Eppendorf tubes and incubated at room temperature for 10 
minutes before being transferred to ice. Animals were then culled with a 3 ml 
intraperitoneal injection of lethobarb (pentobarbitone sodium, Virbec, Milperra, NSW, 
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LETHA450). An initial incision was made into the abdominal region, and the diaphragm 
punctured to retract the lungs. The thoracic cavity was then exposed, and the ribs cut 
away adjacent to the spine. The heart was then removed. Airway draining lymph nodes 
were extracted (Figure 2.2) and placed into GKN-BSA on ice.  
 
A bronchoalveolar lavage (BAL) was then performed with 8 ml of GKN to flush out airway 
cells from the bronchial and alveolar spaces. To do this, the trachea is firstly separated 
from the surrounding tissues using forceps. A piece of thread is then loosely tied around 
the trachea. To allow for both lung and BAL fluid to be collected, without compromising 
the lung tissue, the middle lobe was then also tied off using a piece of thread. A small 
incision was made into the trachea, below the loose knot. The lavage needle is then 
inserted into the incision, and the knot firmly tightened. The lavage needle was attached 
to tubing, connected to a syringe filled with GKN. The lungs are slowly filled with GKN 
and then aspirated back into the syringe. This was then repeated. In the case that the 
initial lavage failed (leaked), the knot was tightened, the syringe refilled with 8 ml of 
GKN, and a single lavage conducted. The recovered BAL fluid was placed into tubes and 





Figure 2.2. Schematic drawing of ADLNs collected (shown in bold). Figure taken from Lehmann 
C, et al. Lymphocytes in the bronchoalveolar space reenter the lung tissue by means of the 
alveolar epithelium, migrate to regional lymph nodes, and subsequently rejoin the systemic 
immune system. The Anatomical Record: An Official Publication of the American Association of 
Anatomists. 2001;264(3):229-36. (152). 
 
 
2.4 Sample preparation   
2.4.1. Lung tissue processing and cell counts 
To extract cells from harvested tissues, lungs were cut into 0.5 mm sections using a 
McIlwain Tissue Chopper. Tissues were then incubated with digestion enzymes in 10 ml 
of GKN containing 10% FCS (GKN-10% FCS), shaking at 37 C. Lung tissue was incubated 
with 1.5 mg/ml of collagenase IV (Worthington Biochemical Corporation, 43E14252), 
and 0.1 mg/ml of DNase-I (Sigma, 9003-98-9) for 90 minutes. During the last 30 minutes, 




Following enzymatic digestion, the samples were thoroughly mixed and filtered through 
a nylon filter, into a 15 ml tube coated with FCS. GKN containing 5% FCS (GKN- 5% FCS) 
was used to wash the filter and flask for any residual cells. The samples were then 
centrifuged at 754 relative centrifugal force (RCF) for 5 minutes at 4 C. 
 
The supernatant was removed from the samples using suction. Lung samples were then 
incubated for four minutes at room temperature in 2 ml of red blood cell lysis buffer. 
Following the addition of GKN, samples were centrifuged for a further 5 minutes at 754 
RCF at 4 C. 
 
To count the extracted cells, the cell pellets were resuspended in 1000 µl of PBS. 10 µl 
of the cell suspension solution was diluted 1:5 with trypan blue (Thermofisher, 
15250061). 10 µl of the cell-trypan blue solution was then loaded onto a 
haemocytometer for cell counting. At least 100 live cells (defined by non-permeability 
to trypan blue) were counted under a light microscope.  
 
Cell concentrations were then calculated according to the following formula:  
cell concentration (cells/ml) = cells counted/rows counted x total rows x dilution factor x 104 
Total cell numbers could then be calculated by accounting for the resuspension volume: 




2.4.2. Airway draining lymph node (ADLN) processing and cell counts 
Cells were extracted from airway draining lymph nodes (ADLNs) by mincing the samples 
by hand using a sterile surgical scalpel. This was then incubated with digestion enzymes 
in 10 ml of GKN-10% FCS, shaking at 37 C for 30 minutes. Digestion enzymes included; 
0.75 mg/ml of collagenase IV, and 0.1 mg/ml of DNase-I. Samples were then thoroughly 
mixed and filtered into a 15 ml tube coated with FCS, through a nylon filter. Samples 
were then centrifuged (Allegra X-12R centrifuge, Beckman Coulter, Indianapolis, United 
States) for 5 minutes at 754 RCF at 4 C.  
 
The supernatant was aspirated, and the cell pellets resuspended in 1000 µl of PBS. 
Lymph nodes required no red blood cell lysis due to low red blood cell numbers. 10 µl 
of the cell suspension solution was diluted 1:5 with trypan blue. 10 µl of the cell-trypan 
blue solution was then loaded onto a haemocytometer. Cells were counted, and 
concentrations calculated, as previously described.  
 
2.4.3. Bronchoalveolar (BAL) fluid processing and cell counts 
Bronchoalveolar lavage fluid was centrifuged at 754 RCF for 5 minutes at 4 C. 1 ml of 
supernatant was collected and frozen at -20 °C for later analysis. The remaining 
supernatant was aspirated, and samples were incubated for 4 minutes in 2 ml of red 
blood cell lysis buffer. After incubation, GKN was added, and the samples were again 




To count extracted cells, the supernatant was aspirated, and the cells resuspended in 
100 µl of PBS. 10 µl of the cell suspension solution was diluted 1:2 with trypan blue. 10 
µl of the cell-trypan blue solution was then loaded onto a haemocytometer for cell 
counting as described above.  
 
20 000 cells from the BAL cell suspension were spun onto a glass microscope slide using 
a cytocentrifuge. Some of these slides were fixed with 4% formaldehyde and sent off to 
an external collaborator for NET detection staining (Figure 3.3.).  
 
The rest of the slides were stained with a Diff-Quick staining kit (IHC, 64851) and counted 
using a light microscope. Macrophages, neutrophils, eosinophils and lymphocytes were 
distinguished by appearance (Figure 2.3.). Cells were only counted if they could be 
clearly classified as one of these four cell types. Areas of the slide that had stained poorly 
were avoided in favour of areas where cells could be more easily distinguished. At least 
300 total cells were counted to allow different cell type proportions to be accurately 
obtained. In the case that 300 cells could not be counted, due to poor staining or low 









2.4.4. Blood preparation  
Blood samples were left to coagulate at room temperature for 10 minutes prior and 
then transferred to an icebox for approximately 7 hours. The blood clot was centrifuged 
for 5 minutes at 754 RCF at 4 C and the remaining serum/supernatant was collected. 
The resulting serum was frozen at -20 C for later IgE/IgG analysis.  
 
2.5. Cell staining for flow cytometry analysis  
For each BAL, lung and ADLN sample, one million cells were transferred to FACS tubes 
and suspended in 1 ml of PBS with 0.1% BSA (PBS-BSA). Samples were then centrifuged 
at 754 RCF for 5 minutes at 4 °C. The supernatant was aspirated, and the cell pellet 
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resuspended in 100 µl of primary antibody master mix (Table 2.5.) for 15 minutes at 4 
°C away from light.  
 
Following incubation, samples were washed with 2 ml of PBS-BSA and centrifuged at 
754 RCF for 5 minutes at 4 °C. The supernatant was aspirated, and the cell pellet was 
then resuspended in 100 µl secondary antibody master mix (Table 2.5.) and incubated 
for 15 minutes 4 °C away from light.  
 
Samples were again washed with 2 ml of PBS-BSA and centrifuged at 754 RCF for 5 
minutes at 4 °C. The supernatant was aspirated, and the cell pellet resuspended in 500 
µl of permeabilisation buffer (1:4 dilution of fixation concentrate [eBioscience, cat: 00-
5123-43 with fixation diluent [eBioscience, cat: 00-5223-56) This was incubated for 30 
minutes, or left overnight, at 4 °C. 
 
Samples were then washed with permeabilisation wash buffer (1:10 dilution of 
permeabilisation) and centrifuged at 754 RCF for 5 minutes. For intracellular staining, 
the supernatant was removed by tipping, and the cells resuspended in 10 µl of FoxP3-
PE antibody solution (1:100, E Bioscience, 12-5773-82) along with any residual buffer 
(approximately 80 µl) that was not removed by tipping. Samples were incubated at 4 °C 
for 30 minutes. Finally, samples were spun at 754 RCF for 5 minutes and resuspended in 




Single stain controls and no stain controls were prepared as above, using 25 000 cells 
from lymph nodes, suspended in 1 ml of PBS-BSA.  
 
Samples were acquired using the LSRII Fortessa (BD Biosciences) using FACSDiva 
Software (version 8.0.1, BD Bioscience). In general, 600 000 - 800 000 events were 
collected, while 50 000 events were collected for single stains. Excitation wavelengths 





















Figure 2.4. Laser excitation wavelengths for each antibody/fluorochrome. Adapted from a 
figure created by Yasmine Khandan.  
51 
 





Company Cat # Dilution Secondary 
Antibody 
Flurochrome Company Cat # Dilution 
CD127 Sheep ThermoFisher PA5-47758 1:25 Anti-sheep APC InVitro F0127 1:10 
CD161 APC-Cy7 Miltenyi 130-102-
715 
1:50      
CCR7 PE-CF594 Jomar 130-102-
715 
1:50      
CD3 FITC BD 557354 1:100      
CD25 Biotin BD 559981 1:100 Streptavidin  PE-Cy5 BD 562284 1:3000 
CD45 BUV395 BD 740258 1:100      
CD43 PerCP-Cy5 Miltenyi 130-107-
688 
1:100      
CD11b V450 BD 562108 1:100      
CD4 PE-Cy7 Bio legend 201516 1:100      
CD172 AF700 InVitro FAB7307N 1:100      
CD8 V500 Miltenyi 130-108-
878 
1:100      
CXCR5 Rabbit Abcam ab225575 1:200 Anti-rabbit BV650 Thermo Q22089 1:50 
CD278 BV605 Biolegend 313538 1:200      
MHC II BV786 BD 744131 1:400      




2.6. Flow data compensation and gating schemes  
Following acquisition using the LSR Fortessa, FlowJo LLC software (version 10.1r7) was 
used for data analysis. Single stain and no stain controls were used to compensate. 
Gating schemes are shown in Figures 3.7, 3.10 and 3.11.  
 
2.7. IgE and IgG ELISA analysis 
IgE and IgG enzyme-linked immunosorbent assay (ELISA) protocols were optimised prior 
to serum analysis (Appendix 2.). 
 
Ovalbumin (5 µg/ml) or 1% BSA, in 50 µl of PBS was coated onto Maxisorb 96 well plates 
(ThermoFisher, 44-2404-21), and left to incubate overnight at 4°C. Following coating, 
plates were washed with PBS containing 0.05% Tween-20 (Sigma, P2287-500ML), using 
a BioTec plate washer (W760). To block unspecific binding, plates were incubated with 
200 µl of PBS containing 1% BSA (PBS- 1% BSA) for two hours at room temperature.   
 
Serum samples, as well as positive (serum from an 8-week-old male BN rat with 
confirmed OVA-specific IgE) and negative (serum from naïve 8-week-old male BN rat) 
controls, were thawed and diluted in PBS-0.1% BSA to a final concentration of 12.5% 
serum. Positive and negative control serums were obtained from a previous study. Each 
sample was added to OVA-coated wells in duplicates, or BSA-coated control wells in 





Plates were washed and incubated with mouse anti-rat IgE antibody (1:2000 in PBS with 
0.1% BSA, Bio-Rad, MCA193) for one hour at room temperature. After another wash, 
plates were incubated with sheep anti-mouse-HRP antibody (Amersham Biosciences, 
NA931) (1:2000 in PBS with 0.1% BSA) for 30 minutes at room temperature. 
 
After another wash, 50 µl of tetramethylbenzidine (TMB) solution (Bio-Rad, BUF056A, 
170811). This solution produces a deep colour during the enzymatic degradation of H2O2 
by HRP. The reaction was then stopped after 30 minutes using 50 µl of orthophosphoric 
acid (1 M). Absorbance was then immediately read using at 450 nm using an EnSpire 
multi-plate reader (Perkin Elmer).  
 
Absorbance values obtained were minused from a blank well value for each plate. BSA-
coated well values were then subtracted from each matched duplicate sample, and the 
two resultant duplicate values were averaged. Average OVA-specific IgE titres, OVA-
specific IgG titres and IgG:IgE ratios, were then calculated for each group. 
 
2.8. DNA quantification 
The DNA content of BAL samples was analysed using a Quant-iT Picogreen dsDNA assay 
kit (Invitrogen, P7581).  
 
Quant-iT Picogreen dsDNA reagent (in a solution of dimethyl sulfoxide) was diluted 




96 well Maxisorb plate (50 µl per well). BAL sample, or lamba DNA standard 
(eBioScience, 108038000) (50 µl) was then sequentially added to the plate in duplicates. 
Serial dilutions of lamba DNA were diluted in GKN. Fluorescence was read immediately 
at 480 nm using the EnSpire multi-plate reader. 
 
2.9. Statistical analysis 
Prism (version 7.0a, GraphPad Software Inc.) was used for statistical analysis and 
graphing of data. Statistical significance between the three baseline experimental 
groups was determined using two-way ANOVA tests with multiple comparisons (Tukey’s 
multiple comparisons test). Statistical significance between the two pre- and post- OVA 
re-challenge groups was determined with multiple t-tests.  
 
Prior to statistical testing, daily weights were transformed (weight/initial weight) for 
each date. 
 
For IgE/IgG analysis, outliers due to experimental error were removed. Values that >50% 
the next lowest sample in that group were removed. This resulted in one value being 
removed from the naïve group. Furthermore, pre- and post- re-challenge values were 
baseline corrected using the following formula (for each of the three treatment groups): 
(mean value / pre-re-challenge mean) x 100. Differences between corrected means were 





Furthermore, naïve and OVA pre-challenge IgE titres were compared using a one-way 
ANOVA. To explore the proportion of sensitised animals, a Fishers Exact test was used 
to compare each sensitised group to the OVA- naïve group.   
 
The DNA content in BAL was compared between the three treatment groups using a 
one-way ANOVA and Tukey’s multiple comparisons test.  
 






3. RESULTS  
In our project, we aimed to determine the role of NETs, or extracellular DNA released 
from dying cells, in allergic disease development, following a viral infection. We 
theorised that NETs are induced during viral respiratory infections, but that they do not 
adequately control the viral disease. Instead, they contribute to the development of 
allergic disease, by contributing to the allergic inflammatory cycle, and their removal will 
be beneficial to patients.  
 
To test this, male adult BN rats were infected with vMC0, as a model for human 
rhinovirus infection. The rats were then sensitised to OVA, as a non-pathogenic model 
allergen. To then test the involvement of NETs or extracellular DNA, half were treated 
with DNase during infection, as a means to efficiently degrade extracellular DNA. These 
groups were then compared to uninfected, sensitised controls.  
 
Approximately one week after the initial OVA exposures, differences between OVA-
specific IgE and airway inflammation was assessed with viral infection and DNase 
treatment. In addition, samples were collected before and after an OVA re-challenge, so 





3.1. vMC0 disease model  
Reduction in body weight, or a reduction in body weight gain, can be used as a measure 
of respiratory viral infections in rodents (125). Animal weights were recorded daily 
following viral infection. According to previous studies, vMC0 titres peak 1-3 days post-
infection, and drop to low/undetectable levels by day five (125). Four days after viral 
infection, weight had not significantly changed between the groups (Figure 3.1.A). This 
suggests only a mild level of infection was established with vMC0.  
 
Bronchoalveolar lavage (BAL) is a method of obtaining cells in the bronchial and alveolar 
spaces of the lungs. BALs were collected three days post virus infection, halfway through 
the OVA exposure scheme, to assess airway inflammation during peak viral infection.  
 
The total number of cells in BAL fluid did not differ between any of the treatment groups 
(Figure 3.1.B.). The total number of macrophages in BAL did not differ between OVA and 
OVA+Virus exposed animals, however macrophage numbers were significantly lower in 
OVA+Virus+DNase animals compared to OVA exposed animals (p<0.05). There were no 
significant difference for any other any other cell types, between any treatment groups. 
However, an increased trend of eosinophils can be seen in the OVA group (p=0.17 and 




























Figure 3.1. vMC0 disease model. Animal weight change during vMC0 infection (days 1-4, with 
vMC0 infection on day 0.5) (A.). Data is presented as means (n ≥ 9) with standard deviation 
indicated by dotted lines. As weights were collected prior to OVA re-challenge, pre- and post- 
OVA-rechallenge groups were combined. BAL cell numbers during peak vMC0 infection (B and 
C.). BAL fluid samples were collected on day 3 post viral infection, 24 hrs after the second OVA 
intranasal. Statistical difference was calculated using a two-way ANOVA (with Tukey’s multiple 
comparisons test) and indicated as *p<0.05. Data is shown as means (n = 3) with standard 
deviations.  
  






































































































3.2. OVA sensitisation model 
To investigate if virus infection influenced sensitisation to OVA, virus infected rats were 
exposed to OVA. Following OVA exposure, each experimental groups OVA-specific IgE 
levels were compared to those of non-sensitised, OVA-naïve controls. This was done to 
confirm that OVA sensitisation was established in our animals and was achieved using 
an enzyme-linked immunosorbent assay (ELISA). OVA-specific IgE titres were 
significantly increased in the OVA exposed and OVA+Virus groups, compared to naïve 
controls (p<0.01 and p<0.05, respectively). OVA-specific IgE titres were not significantly 
different in the OVA+Virus+DNase group compared to naïve animals (p=0.22) (Figure 
3.2.A.).  
 
To explore the proportion of sensitised animals in each experimental group, Fisher’s 
exact tests were performed. Animals were classed as sensitised if their IgE level 
(absorbance value) was greater than the mean of the OVA-naïve groups, plus two 
standard deviations. OVA and OVA+Virus exposed groups had significantly higher 
proportions of sensitised animals (100%) when compared to OVA-naïve controls 
(p<0.01). The OVA+Virus+DNase group did not display a significantly higher proportion 
of sensitised animals (60%) when compared to OVA-naïve controls (Figure 3.2.B). This 


















Figure 3.2. OVA sensitisation. IgE titres for OVA sensitised (pre-OVA re-challenge) experimental 
groups, compared to OVA-naïve controls (A.). The dotted line represents the sensitisation cut off 
(naïve group mean plus two standard deviations) used for Chi-Square analysis. Statistical 
significance was calculated using a one-way ANOVA and shown as *p<0.05. Data is shown as 
means (n ≥ 4) with standard deviations.  The proportion of OVA sensitised and non-sensitised 
animals based on OVA-naïve controls (B.). Statistical difference was calculated using a Fishers exact 




























































































3.3. Quantification of DNA content in BAL samples 
 
DNase is commonly used to cleave extracellular DNA released by necrotic neutrophils. 
In our model, we used DNase to break down NETs formed during viral infection. DNA 
and MPO content (two major NET components) in BAL samples were confirmed with 








Figure 3.3. Potential NETs on a virally infected BAL slide. BAL slides were stained for DNA (blue) and 
myeloid peroxidase (MPO) (green) by an external collaborator.  
 
To assess the effect of DNase treatment on DNA in the airways, DNA was quantified in 
BAL fluid three days after virus infection, after two daily DNase intranasals (Figure 2.1.). 
The DNA content in BAL did not significantly differ in OVA, OVA+Virus or 



















Figure 3.4. DNA content in BAL samples (three days post-vMC0 infection).  Data is shown as means 












































3.4. OVA-specific IgE and IgG titres 
To then assess how virus infections and extracellular DNA influenced the allergic recall 
response, OVA-specific IgE was measured 24 hours post- OVA re-challenge and 
compared to pre-re-challenge levels. OVA-specific IgG was also measured post-re-
challenge and compared to pre-re-challenge values, as an important antibody in the 
anti-viral response.  
 
As previously described (Figure 3.2.), baseline (pre-re-challenge) OVA-specific IgE titres 
did not significantly differ between treatment groups. Similarly, baseline OVA-specific 
IgG titres did not significantly differ between treatment groups (Figure 3.5.A.).  
 
Allergic recall was then compared for each treatment group, by comparing IgE levels 
pre- and post- allergic re-challenge. No significant difference in the allergic recall was 
seen for any of the treatment groups, suggesting that a re-call response was not 
observed (Figure 3.5.B.). Additionally, no difference was observed between pre- and 
post- IgG levels (Figure 3.5.C.). 
 
Finally, to account for competitive binding of IgE and IgG, the ratio of IgG:IgE was also 
analysed (Figure 3.5.D.). The ratio of OVA-specific IgG to OVA-specific IgE did not 








Figure 3.5. Serum IgE and IgG titres pre- and post- OVA re-challenge. IgG pre-re-challenge titres (A.). 
Data is presented as means (n ≥ 4) with standard deviations. IgE pre-re-challenge titres are shown 
in Figure 3.2.  
IgE (B.) and IgG (C.) titres from serum samples. Data has been corrected to pre-re-challenge means 
(n ≥ 4) and shown as corrected means with standard error means. Statistical difference between 
pre- and post-re-challenge groups was determined using a paired t-test. No significant 
differences were seen (ns).  
As IgG may have competitively bound to OVA in the IgE assay, IgE titres were also analysed as a ratio 
with IgG (D.). Data is presented as means (n ≥ 4) with standard deviations.  
Statistical significance between treatment groups at baseline (pre-re-challenge) was determined 







































































































































































3.5. Cellular airway infiltration 
We further assessed how viral infections and extracellular DNA influenced the allergic 
recall response, by assessing airway cell infiltration in response to OVA re-challenge.  
 
3.5.1 Innate immune response  
Assessing total cell numbers in BAL did not reveal any difference between any of our 
three treatment groups prior to OVA re-challenge (Figure 3.6.A.). In addition, none of 
the groups appeared to respond to OVA re-challenge with infiltration of cells into the 
airways, as pre- and post- OVA, re-challenge cell numbers, did not significantly differ for 
any cell type (Figure 3.6.).  
 
3.5.2. Adaptive immune response 
To further analyse the cellular differences in airways after virus infection and OVA 
sensitisation, we used multiparameter flow cytometry analysis. Three airway tissues 
were collected (lung, ADLNs and BAL fluid), however, due to time constraints, only lung 
data was statistically analysed for this project. As innate immune cell proportions were 
analysed in BAL differential counts, analysis focused on cell involved in adaptive 
immunity; namely T cells, B cells and DCs.  
 
3.5.2.1 T cells 
T cells were differentiated according to Figure 3.7. They were firstly subdivided into 
CD4+ T cells and CD4- T cells. Our CD8 marker was unable to be used due to poor 
staining. CD4+ T cells were then further divided by their expression of FoxP3, to split 




Firstly, baseline levels of T cell subtypes were compared for our three experimental 
groups. Baseline CD4+ or CD4- T cells did not differ between any groups. However, when 
CD4+ T cells were subdivided into Treg (FoxP3+) and non-Tregs (FoxP3-), Treg cells were 
markedly increased in OVA+Virus+DNase groups, when compared to OVA+Virus and 
OVA groups (p<0.01 and p<0.001) (Figure 3.8.C.).  
 
Next, allergic re-call was assessed, by determining if there were any differences between 
pre- and post- OVA-re-challenge for any of the experimental groups. No differences 
were observed between pre-and post- OVA-re-challenge for any of the experimental 
groups (Figure 3.8.).  
 
Furthermore, mean fluorescent intensities (mfi’s) were compared from different T cell 
subtypes. Baseline CD25 mfi’s did not differ between experimental groups for Treg, non-
Tregs and CD4- T cells. Baseline FoxP3 mfi’s were significantly amplified in 
OVA+Virus+DNase when compared to OVA (Figure 3.9.B.). However, neither CD25 or 
FoxP3 mfi’s differed with OVA re-challenge for any treatment groups (Figure 3.9.). 









Figure 3.6. BAL cell numbers. Total cell numbers recovered from BALs (A.).  Eosinophil (B.), 
macrophage (C.), neutrophil (D.) and lymphocyte (E.) total cell numbers, from BAL differential 
counts. No significant difference (ns) was seen between pre- and post- OVA re-challenge groups, 
or between any of the treatment groups (as shown by multiple t-tests and a two-way ANOVA, 
respectively). Data is shown as means (n ≥ 4 per group) with standard deviations. All groups were 
sensitised with four daily OVA intranasals and samples were collected one week after 

















































































































































































Figure 3.7. T cell gating scheme. Firstly, forward and side scatter was used to create a cell gate (A.). T cells were defined as CD11b-, CD3+ (B.) and CD45+ 
(C). T cells were then subdivided into CD4+ and CD4- subtypes (D.). CD4+ T cells were further classified based on their expression of FoxP3 (E.).  
 
 




















Figure 3.8. T cell proportions. CD4+ T cell proportions (A.), CD4- T cell proportions (B.), FoxP3+ 
CD4+ T cell proportions (C.) and FoxP3- CD4+ T cell proportions (D.). Statistical significance 
between groups was determined using a two-way ANOVA with Tukey’s multiple comparisons, 
shown as**p<0.01, ***p<0.001. Statistical significance between pre- and post- samples were 
determined using multiple t-tests, and shown as ns = no significance. Data is shown as means 












































































































































































































Figure 3.9. CD25 and FoxP3 mfi’s for T cells. Tregs CD25 (A.)  and FOXP3 mfi’s (B.). Non-Tregs 
CD25 mfi (C.). CD4- T cell CD25 mfi (D.). Statistical significance between groups was determined 
using a two-way ANOVA with Tukey’s multiple comparisons, shown as**p<0.01. Statistical 
significance between pre- and post- samples were determined using multiple t-tests and shown 



























































































































































































3.5.2.2 Dendritic cells and monocytes  
DCs and monocyte proportions were assessed, due to their role in antigen presentation 
to lymphocytes. DCs can be subdivided into conventional DCs (cDCs) and plasmacytoid 
DCs (pDCs). cDCs were gated according to Figure 3.10., while pDCs were gated according 
to Figure 3.11. Baseline cDC proportions did not differ between any of our experimental 
groups (Figure 3.12.). Similarly, pDC proportions at baseline did not differ between any 
treatment groups (Figure 3.12.). DCs were also assessed for any proportion changes with 
OVA re-challenge. DC proportions did not significantly change with OVA re-challenge for 
any treatment groups (Figure 3.12.).  
 
Monocyte gating can be seen in Figure 3.10. Monocyte baseline proportions did not 
differ between any of our treatment groups. Monocyte proportions were also 
unchanged between pre- and post- OVA re-challenge for any of the treatment groups 
(Figure 3.13.B.). 
 
3.5.2.3 B cells  
B cells were gated according to Figure 3.11. Baseline B cell proportions did not differ 
between treatment groups. Furthermore, B cell proportions did not differ with OVA re-
challenge for any treatment group (Figure 3.13.A).  
 
8.5.2.4 Adaptive immunity findings 
Together, these findings suggest the adaptive immune response did not differ between 




induce a Treg response, as observed by increased Treg proportions, and increased Treg 
FoxP3 mfi’s, in the OVA+Virus+DNase experimental group, compared to OVA and 









Figure 3.10. Conventional dendritic cell (cDC) and monocyte gating scheme. Forward and side scatter was used to create a cell gate (A.). cDCs were 
defined as CD11b+, CD3- (B.), CD161- (C.), and MHCII+ (RT1B+) (D.). cDCs were then further subdivided by CD4 and CD172 expression (E.). Monocytes 
were defined as CD11b+, CD3- (B.), CD161- (C.), MHCII- (RT1B-) (D.), CD4+ and side scatter (F.).  
  















Figure 3.11. Plasmacytoid dendritic cell (pDC) and B cell gating scheme. Forward and side scatter was used to create a cell gate (A.). Both were defined 
as CD3-, CD11b- (B.) and CD45R+ (C.). B cells and pDCs were then distinguished by their CD4 and MHCII (RTB1) expression (D.).  
 





Figure 3.12. Plasmacytoid dendritic cell (pDC) and conventional dendritic cell (cDC) proportions 
(out of cell gate). cDCs were then analysed as DP (CD4+ and CD172+) cDCs (C.), DN (CD4- and 
CD172-) cDCs (D.) and CD4-, CD172+ cDCs (E.). ns = no significance between pre-and post-




























































































































































































































Figure 3.13.B cell (A.) and monocyte (B.) proportions (out of cell gate). ns = no significance 



















































































4. DISCUSSION  
Although respiratory viral infections are strongly correlated with development of allergic 
asthma, little is known about its impact on IgE sensitisation, due to conflicting and 
limited research. Furthermore, it is not known precisely how viral infection may produce 
(or alternatively protect) against allergic disease. Our project aimed to explore this link 
between virus and allergy. In addition, we tested if this potential effect was mediated 
through NETs, given these were recently reported to be induced during viral infections 
(41, 153) and induce a Th2 response (144).  
 
To do this, rats were infected with vMC0, as a model of HRV infection. Animals were 
then given four daily OVA exposures, as a non-pathogenic model allergen. The BN rat 
strain was used, as they are naturally susceptible to Th2 inflammation. This both 
removed the need for an adjuvant and provided a more clinically relevant model, as 
previous skewing towards a Th2 effector response often proceeds allergy development 
(102, 154). To then test the effect of extracellular DNA on allergic sensitisation, DNA was 
degraded using DNase, as this has been previously shown to degrade NETs (41). In 
addition to assessing virus and NET influences on IgE sensitisation, we determined if viral 
infection and NETs influenced the subsequent allergic recall response, by re-exposing 
the animals to OVA one week after their last sensitising exposure. 
 
4.1. vMC0 infection model  
Rhinovirus does not naturally infect rodents (149) and thus does not establish the clinical 
and immunological outcomes seen in HRV infection. vMC0 belongs to the same 
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Picornaviridae virus family as HRV (149, 155) and establishes a lower airway 
inflammatory response in BN rats, thus mimicking features of HRV inflammation (125). 
Previous studies found infection with 107 PFU of attenuated vMC0 resulted in significant 
reductions in weight gain percentage three days after viral infection, compared to those who 
received the vehicle control (supernatant from uninfected HeLa cultures). Furthermore, they 
saw no significant difference in weight gain percentage when UV-inactivated vMC0 was 
compared to vehicle controls (125). Interestingly, our model of vMC0 infection saw no 
significant differences in weights between our three experimental groups. Four days 
post-infection, both virally infected and non-infected groups displayed no differences in 
weight gain percentages (Figure 3.1.A). This suggests only a mild level of vMC0 infection 
was established in our model. This is in accordance with previous work from our 
research group, where the virus can be detected in BN rats 1-2 days post-infection, even 
in the absence of inflammatory symptoms (147). 
 
To further explore the effects of vMC0 infection, cellular infiltrates were analysed during 
suspected peak of viral infection. Peak infection was expected to occur between days 1-
3 post-inoculation, as significant viral titres have been observed in lung and BAL samples 
between these days, in a similar model (125, 147). BAL samples were collected on day 3 
post-inoculation, and the number of airway-infiltrating cell types were compared 
between our treatment groups. This analysis also occurred mid-way through the 
sensitisation process, with and without virus infection/extracellular DNA, and thus the 
cellular response during sensitisation could be observed, as previously demonstrated in 
OVA sensitisation models (27, 123). The total number of BAL cells did not significantly 
differ between treatment groups (Figure 3.1.B.). The number of macrophages in BAL 
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fluid did not differ between OVA and OVA+Virus groups. However, total macrophage 
numbers were reduced in OVA+Virus+DNase animals, compared to the OVA only group 
(Figure 3.1.C.). No other cell type displayed significant changes in numbers when our 
three groups were compared. Yet, there was a trend that eosinophils cell numbers were 
increased in the OVA group when compared to the OVA+Virus and the 
OVA+Virus+DNase groups. These results are different to what was previously observed 
during vMC0 infection in BN rats, where a significant infiltration of neutrophils and 
lymphocytes were observed three days post-infection (125).  
 
Human models assessing BAL cell numbers in HRV infected allergic individuals, typically see 
increased eosinophil infiltration (156-159). Hence, it interesting that we did not observe a 
similar increase in eosinophil numbers, in our model of virus infection and sensitisation. 
Such disparities between previous studies and our research project may indicate that a 
lower respiratory infection was not achieved in our model. As a previous study still observed 
a significant increase in neutrophils and lymphocytes when the vMC0 dosage was lowered 
ten-fold (125) it is unlikely the dosage we used was too low to achieve infection. However, it 
is important to note that we did not have a naïve control group, as non-infected animals 
were exposed to OVA, which would have likely affected immune cells in the respiratory 
tissues.  
 
Another reason why we may not have observed cellular differences is that vMC0 had already 
been resolved by day three post-infection. While one previous study of vMC0 infection in 
BN rats still observed significant cellular infiltration and viral titres day three post-infection, 
the highest levels were observed one day post-infection (125). Furthermore, previous 
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studies by our group found that viral loads peaked at day one and had largely resolved by 
day three (147). These results may explain why we failed to see any significant cellular 
infiltration in response to virus three days after vMC0 infection. The same study found total 
BAL cellularity was significantly increased at day one post-infection when compared to 
uninfected controls. They further observed an influx of macrophages with virus infection, 
and a notable lack of neutrophil recruitment in BAL fluid when sensitised BNs were 
compared to a Th2-low strain. This may explain why we failed to see the typical neutrophilic 
anti-viral response. They suggested that BN models likely exhibit a defective antiviral 
immune response, as observed in some models of human allergic disease (147). For 
example, this type of defective anti-viral response has been seen in peripheral blood 
mononuclear cells from atopic asthma patients in response to HRV. Papadopoulos and 
colleagues observed significantly lower levels of IFN-γ and IL-2 compared to non-atopic 
patients, indicating that the Th1 response to viral infections may be defective in atopic 
individuals (130).  
 
Other murine models of Th2 high HRV infection have typically involved Balb/c mice (122, 
160-162). These models typically display acute neutrophilic inflammation following viral 
infection. Potentially, these models may be a more accurate model for analyzing the effect 
of virally induced-NETs with DNase degradation. Future studies should look to confirm vMC0 
infection by assessing viral titres in lung tissues three days post-inoculation, as well as 
assessing cellularity and weight changes. Furthermore, cellular infiltrates and viral titres 




4.2. OVA sensitisation model 
BN rats were used for OVA sensitisation, as their Th2 pre-disposition leads to a more 
pronounced allergic response, compared to less Th2-prone strains (147). Traditional 
methods of OVA sensitisation involves an intraperitoneal injection with an OVA/Alum 
solution, and re-challenging via nebulisation with 1% OVA solution (123). However, 
more recently, OVA sensitisation has been achieved with four consecutive daily OVA 
intranasals (148). This model is particularly suitable, as sensitisation is achieved without 
an adjuvant which may mask subtle differences in degree of sensitisation. We confirmed 
that OVA sensitisation had been achieved in our model by comparing OVA-specific IgE 
levels in serum (in pre-OVA re-challenge groups) to naïve controls, using an ELISA (Figure 
3.2.). 
 
4.3. Effect of virus/DNase treatment on allergic sensitisation 
OVA-specific IgE was significantly higher in OVA and OVA+Virus groups, compared to 
naïve controls (Figure 3.2.). In these groups, 100% of our animals (n=6) were sensitised 
(sensitisation was defined as titres above two standard deviations of the mean of naïve 
rats). There appeared to be no difference between OVA and OVA+Virus groups, 
suggesting virus infection did not alter sensitisation. Interestingly, OVA+Virus+DNase 
groups failed to establish significantly higher OVA-specific IgE titres, compared to naïve 
controls, indicating that DNase treatment may be reducing the risk of OVA sensitisation. 
Only 60% of animals in this group (n=5) established OVA sensitisation (Figure 3.2.).  
 
In addition to the level of IgE, induction of additional Ig isoforms may influence allergic 
disease. Therefore, we also measured OVA-specific IgG titres in our three groups and 
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compared IgG:IgE ratios (Figure 3.5.). No difference was observed between any of the 
groups, suggesting the effect observed in the OVA+Virus+DNase group was specific to 
IgE induction, and not IgG. However, a low sample size (n ≥ 4), substantially reduces the 
power of this result. This was an over-arching limitation of our study design. 
 
To assess why DNase might reduce the rate of OVA sensitisation, the DNA content in 
BAL fluid was measured three days post-vMC0-inoculation, following two OVA/DNase 
intranasals. DNA content in BAL fluid did not significantly differ between our three 
treatment groups (Figure 3.4.), indicating that virus infection and DNase treatment did 
not alter DNA content. This suggests differences to sensitisation occurred independently 
of DNA in BAL fluid and not due to reduced DNA content. During our optimisation of 
DNase dosages (Appendix 6.1.), increased DNase concentrations interestingly correlated 
with an increased trend in BAL DNA content, in female BN rats with elevated baseline 
airway inflammation (Section 6.1., Figure 6.3.). In a bovine model of viral respiratory 
infection (with a bovine respiratory syncytial virus), DNase treatment resulted in NET 
degradation, and an increase in BAL DNA content (41). While at first counter-intuitive, 
this increase in DNA suggests that DNase treatment is fragmenting and “freeing” DNA 
previously bound in NETs or inflammatory mucus plugs allowing detection in BAL (41). 
We may not have observed a similar change in our main treatment experiments, due to 
the low level of inflammation in BN males, compared to BN females (unpublished 
preliminary data). This reflects what is seen in another murine model of allergic 
sensitisation, where female Balb/C mice are typically more susceptible to Th2 
inflammation than males (162). Additionally, the bovine model described above was 
characterised by neutrophilic inflammation, typical of severe RSV lower tract infection 
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in children (41, 163, 164). Hence, this suggests that in our model of mild respiratory 
infection, substantial amounts of NETs/ extracellular DNA may not have been produced. 
Using confocal microscopy, our collaborators did detect signs of NETs in BAL fluid (Figure 
3.3.). However, this is yet to be systematically analysed.  
 
To further assess how viral infections and extracellular DNA influence the airway immune 
composition, cellular airway infiltrates were examined. Both innate and adaptive responses 
were considered, by analyzing both BAL fluid and lung flow cytometry data, respectively. 
Baseline cell composition in BAL did not significantly differ between the three groups, when 
samples were collected at one week after infection/sensitisation, prior to re-challenge. This 
is particularly interesting, as a decrease in macrophages was seen for our OVA+Virus+DNase 
group, compared to OVA only rodents, when samples were collected day three-post 
infection.  This would suggest that DNase may alter the acute cellular response to infection, 
but that this difference is not noticeable one week after infection. This is not unusual, as 
innate responses are typically rapid, but short-lived (165). As no differences were observed 
for any cell types between our three experimental groups a week after infection, and no 
differences for any other cell types three-days post-infection, it would appear that virus 
infection is not altering the cellular response during the sensitisation process.  
 
Since no difference was observed in major cell subtypes with virus infection and DNase 
treatment, the decreased rate of sensitisation in our OVA+Virus+DNase group may not 
translate to a difference in airway composition. In Cortjens and colleagues non-sensitised 
model, observing no difference between infected and non-infected groups suggested that 
NETs were not integral to the host-anti-viral response (41). However, observing the same in 
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our model, more likely suggests that NETs/ extracellular DNA may be involved in the 
sensitisation process, but not required for viral defence. However, due to the proposed 
defective anti-viral response in the rat strain used (147), it may be useful to confirm this 
finding in a non-Th2 high strain, while still allergically sensitising, to confirm if NETs play a 
greater role in viral defence. However, designing such a model would be complicated, as Th2 
skewing is a typical pre-disposition observed in atopic individuals, and currently required for 
most atopic animal models (122, 123, 166, 167).  
 
Furthermore, as our samples were collected one week after infection, we expected to 
observe variations between our three groups considering the expected activation of the 
adaptive immune response during the viral infection (3, 91, 168). To analyse this, 
proportions of cells involved in viral immunity was assessed with multiparameter flow 
cytometry. T cells, B cells, monocytes and DC proportions were considered, as the major 
cell types involved with the adaptive immune response. DC and monocyte proportions 
were considered, due to their role in antigen presentation to B and T cells (3). We 
expected possible changes reflecting a Th1 (viral) or Th2 (allergic) response. Virus 
infection during allergy development has been proposed to be both protective and 
inductive towards allergy sensitisation in previous models (169-172). 
 
We uncovered no differences in B cell proportions between our three treatment groups 
(Figure 3.13.). Furthermore, no differences were seen between baseline proportions for 
monocyte and DCs (Figure 3.13.). Baseline CD4+ and CD4- T cell proportions further 
uncovered no significant differences between treatment groups. However, when CD4+ 
cells were divided into Treg and non- Treg cells, DNase treatment was found to markedly 
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heighten Treg populations, when compared to both OVA and OVA+Virus groups (Figure 
3.8.). 
 
To explore this difference further, expression levels (as mfi’s) were compared for two 
main Treg activation markers, CD25 and FoxP3. CD25 forms part of the IL-2 receptor (IL-
2 receptor alpha chain) together with CD122 and CD132 and is expressed on activated 
Tregs. FoxP3 is a master regulatory transcription factor crucial for Treg development and 
function (58). Considering the mfi’s of these markers, we could examine the level of 
expression within each treatment group, and thus determine Treg activation levels for 
each treatment group. Interestingly, Treg CD25 mfi’s did not significantly differ between 
our treatment groups, suggesting that while a higher proportion of Tregs were observed 
with DNase treatment, these cells were not significantly more activated. Yet, Treg FoxP3 
mfi’s were higher for DNase treatment groups, but only when compared to OVA 
exposed animals. This suggests DNase treatment increases FoxP3 expression on Tregs, 
as well as increasing Treg proportions. 
 
Tregs are a subset of T cells involved in immune suppression, by actively preventing the 
activation and expansion of activated lymphocytes. This is an important function, in 
particular for preventing excess-inflammatory damage following an infection and 
preventing autoimmune disorders. Depletion of Tregs has been shown to augment the 
immune response to both self and non-self antigens. Tregs have been shown to suppress 
allergy, thus, Treg deficiencies can evoke a T cell-mediated autoimmunity and 




The transcription factor FoxP3 expression is a critical component for Treg 
differentiation. Disruption of FoxP3 in both human and murine models result in 
proliferative lymphocyte diseases (56, 58, 174, 175). Foxp3 deficient mice lack Tregs, 
while mice that over-express Foxp3 possess elevated levels of Tregs (55, 58). Hence, 
increased expression of FoxP3 by Tregs, likely induced more Treg differentiation, 
increasing Treg proportions (56, 70, 176). 
 
Expansion of Tregs has been used to induce tolerance following tissue transplants, by 
suppressing graft rejection, through inhibiting activation and expansion of Teffs. 
Additionally, recruited naïve T cells may differentiate into Tregs, due to FoxP3 
expression, further boosting immuno-suppression. The same principle could be applied 
to autoimmune disease and allergy (58, 68, 70, 160, 171, 173, 176-178). Hence, the 
higher proportions of Tregs observed with DNase treatment, likely indicates a protective 
function towards atopy and possible association with lower levels of OVA-specific IgE, in 
this group. This in an exciting finding, as it alludes to an inducible protective response 
with DNase treatment. The debate regarding whether viral infections are inductive or 
protective against allergic disease indicates the complex nature of allergic disease 
development. Here, we show that DNase treatment following a viral infection may 
induce a regulatory response, capable of reducing allergy sensitisation.  
 
4.4. Effect of virus/DNase treatment on allergic recall  
 
Along with comparing differences between our treatment groups at baseline, each 
group was additionally re-challenged with OVA one week after sensitisation/infection, 
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to determine if virus infection/DNase treatment altered the response to allergen re-
challenge.  
 
OVA-specific IgE titres were expected to increase in response to allergen-re-challenge, 
indicative of an allergic response. However, this was not seen for any of our treatment 
groups (Figure 3.5.). Similarly, analysis of innate and adaptive cells uncovered no 
differences between pre-and post-OVA re-challenge groups, for any treatment groups.  
 
The lack of observable re-call response suggests that our animals failed to establish 
symptomatic allergic disease, despite establishing OVA sensitisation. This result mimics 
a common situation in the human population. In the Western world, 50% of people will 
react positively to a skin prick test, indicating that they are sensitised to a particular 
antigen. However, only a further 50% of these individuals will actually develop allergic 
symptoms if exposed to the allergen (179-181).  
 
A previous model of OVA sensitisation and vMC0 infection similarly saw no significant 
differences in OVA-specific IgE titres, when OVA sensitised animals were compared to 
those co-exposed to virus and OVA. However, this model involved sensitising with an 
intraperitoneal OVA/Alum injection, two weeks prior to vMC0 infection (147). Including 
an adjuvant in this way may be required to generate high IgE titres that result in an 
allergic recall response. This finding highlights the complexity of the allergic disease, by 
emphasising the importance of sensitisation in conjunction with an adjuvant. Viral 
infection, in this case, does not appear to enhance the immune response in the same 
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way as the Alum adjuvant, indicating that something else may be required at the time 
of allergen exposure to trigger allergic disease. Future studies should consider using a 
stronger viral infection model, such as a higher dose and/or more virulent virus strain. 
 
4.5. Future directions 
Early life respiratory infections may be both protective or inductive of allergic disease. 
NETs, or extracellular DNA, induced by viral infection, were proposed to be inductive, by 
inducing a Th2 response. In the current model, we failed to observe any effect of viral 
infection on IgE sensitisation. However, a protective function of DNase treatment was 
observed. Rather than reducing the effect seen from viral infection, DNase treatment 
induced Treg differentiation or recruitment to the airways. Tregs have been shown to 
protect against infection, by suppressing the Th2 effector response. Hence, it would 
appear an immunomodulation approach, by increasing regulatory cells, is likely to 
promote protection against allergy development.  
 
However, this effect has only been seen in a single rat strain. As shown by the abundant, 
conflicting evidence regarding virus infection and allergy, allergic disease development 
is a complex and developing field. This model includes one genetic strain, with high 
baseline Th2 inflammation, and a potentially defective viral response. Furthermore, this 
study only included a single, low virulence viral strain, where a low level of respiratory 
infection was produced. The ability of DNase treatment to induce a protective, 
regulatory response, will need to be applied to multiple genetic phenotypes, including 
testing in both genders, to establish its applicability to human disease models. 
Moreover, all experiments were conducted in adult rats, while human allergy 
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development typically occurs in younger individuals. Nevertheless, these findings add to 
the ever-increasing mass of knowledge surrounding allergic disease development, and 
will hopefully contribute to reducing the ever increasing burden of allergic disease on 





5. CONCLUSIONS  
 
This project initially aimed to explore how virus infection may contribute to allergic 
disease development, and test the involvement of NETs or extracellular DNA, recently 
reported to be produced during viral respiratory infections. This was done by treating 
virally infected animals with DNase, a drug previously shown to efficiently degrade NETs. 
Although no effect on IgE sensitisation was observed due to virus infection, DNase 
treatment, reduced the risk of IgE sensitisation and increased Treg proportions in the 
lungs. Furthermore, Tregs in DNase treated animals displayed higher levels of FoxP3, 
compared to OVA exposed animals. This likely suggests that DNase treatment is 
encouraging a regulatory response, potentially protecting against allergic sensitisation.  
 
While we initially sought to utilise DNase to degrade NETs and reduce a virally induced 
Th2 response, we instead saw little difference between the immune profiles of virally 
infected and non-infected sensitised animals. Future studies should, therefore, use a 
more virulent virus strain to ensure detectable disease. Ideally, they should also utilize 
increased sample numbers to increase statistical significance. In summary, the 
protective, immunoregulatory response following DNase treatment, has uncovered a 
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This chapter contains the optimisation protocols and findings used to determine 
protocols used in the main experimental methods. DNase dosage was decided from a 
series of dose safety experiments. Final IgE and IgG ELISA protocols, were also based off 
a series of optimisation protocols. Both the methods and findings for both these 
optimisations are outlined below.  
 
6.1. DNase safety testing  
6.1.1. Experimental design 
The OVA sensitisation and vMC0 infection protocols were established in the lab, 
however, before we could start using the model, DNase-I exposure needed to be 
optimised and deemed safe in our model. For this purpose, 8-week-old female BN rats 
received DNase-I intranasals, ranging from 0-200 µg/ml, according to Table 8.1. DNase 
was given intranasally in a solution of sterile PBS (100 µl), under isoflurane aesthetic. 
This treatment commenced for four consecutive days in accordance with further 
experimental plans (Figure 2.1.). To assess cell viability, cells from bronchoalveolar 
lavage (BAL) and lung tissue were collected 24 hours after the last DNase intranasal, as 










Table 6.1. DNase concentrations and number of rats used for DNase safety testing    














Figure 6.1. DNA safety testing. Animals received four daily DNase intranasals. Lung and BAL 








BAL fluid and lung tissue samples were processed as per method section 2.4. For lung and BAL 
samples, cells were stained with trypan blue to discriminate dead (positive) and live (negative) 
cells. Cells were then counted so that dead cell proportions could be obtained. Proportion of cell 
types in the BAL samples were also counted as previously described (Section 2.4.3.). To assess if 
DNase treatment had an impact on DNA released into the BAL, the DNA content of BAL samples 
was analysed as described in the DNA quantification section (Section 2.11.). 
 
In addition to trypan blue staining, BAL and lung samples were stained using Annexin-V and 
Viablity dye and assessed using flow cytometry. The staining protocol was as previously 
described (Section 2.5), however, included a different set of antibodies and viability stains to 
assess if different type of immune cells responded differently to DNase exposure (Table 8.2.). 
Single stains were measured for each antibody, as well as annexin-V and viability dye 
fluorescence minus one’s (FMOs).   
 
Table 6.2. Antibody panel and viability dyes  
Primary Antibody  Flurochrome 
/Host 
Dilution Company Cat 
CD3 FITC 1:100 BD 557354 
MHCII PerCP-Cy5 1: 100 BD 744131 
Annexin-V BV510 1:80 Biolegend 640937 







6.1.2. Dead cell proportions  
The proportion of dead cells for each DNase dosage was determined using flow cytometry 
(Figure 6.2.) and trypan blue exclusion. Using either of the methods, no significant difference in 
dead cells with increasing DNase doses was observed for BAL or lung samples (Figure 6.2.A.) 
Furthermore, these two methods were compared, and no significant differences were observed 
at any DNase dose (Figure 6.2.B).  
 
Interestingly, both BAL and lung baseline dead cell proportions were high. This was likely due to 
the use of female BN rats. The BN strain display lungs with high baseline inflammation (145). In 
particular, females have a higher level of inflammation compared to males (27, 146). Although 
male rats were used for the main project, due to the limited availability of animals, females were 
the only available option for this optimisation in the limited timeframe. Despite this limitation, 
these findings show DNase did not influence cell viability even in an inflammatory environment.  
 
6.1.3. BAL differential counts 
BAL differential counts were also analysed, to determine if airway inflammation was affected by 
the different dosages. Interestingly, a significant increase in the number of eosinophils was seen 
with the highest DNase dose (200 µg/ml) (Figure 6.2.D.). Given the elevated baseline and 
variability observed within BN females (unpublished data), this dose was further tested in male 
rats. However, due to the limited time frame and available animals, a direct comparison of male 
and females was not achievable. Instead, samples from another aspect of the study were used. 
A small number of male rats received 200 µg/ml DNase and 1 mg/ml OVA intranasals over two 
days, and BAL samples were collected 24 hours after the last exposure (Figure 2.1). Although 
this is not directly comparable to the females, only limited eosinophil infiltration was observed 
at this timepoint in male rats (Figure 6.2.E.). This suggests the increased eosinophil infiltration 
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observed at 200 ug/ml DNase was a female only effect, associated with their high baseline 
inflammation.  
 
While unable to conclude that this difference was caused by gender, due to the numerous 
variables introduced by this comparison, this outcome may explain why a high eosinophil 
proportion was observed with the highest DNase dose. We propose that the increase in 
eosinophils was due to the use of female test subjects, rather than the 200 µg/ml DNase dose, 
since it remained within the normal range of female variation. Future safety tests should utilise 
animals of the same gender, as well as strain and age, to test this idea.  
 
6.1.4. DNA content of BAL samples  
The DNA content in BAL fluid was quantified to determine the effect of increasing DNase 
concentrations (Section 2.11.). We hypothesised that increasing the DNase concentration would 
proportionally reduce the DNA content in BAL fluid. Interestingly, the opposite appears to be 
true. A significant increase in DNA was observed between 0 and 200 µg/ml, and 50 and 200 
µg/ml of DNase (p<0.05, p<0.01, respectively) (Figure 6.3.). An explanation for this may be that 
the increased amount of DNase results in an increased amount of released DNA, airway 









Figure 6.2. DNase safety testing. (A.) Gating scheme used to assess cell viability. Cells were gated 
according to forward and side scatter. Dead cell proportions were then obtained using Annexin 
V and Viability dye. (B.) Dead cell proportions for BAL and lung samples. (C.). Comparison of 
trypan blue and flow cytometry-based methods. (D.) BAL cell type numbers for each DNase dose. 
Dosages were compared for each cell type using a two-way ANOVA with Tukey’s multiple 
comparisons, and significance shown as **** p<.0.0001. (E.) Male and female BAL cell type 
proportions. Statistical significance between male and females was determined using multiple t 




























No significant difference found in dead cell content for 



























No difference observed between trypan blue 









































































































Increased eosinophil infiltration was seen with a 200 µg/ml DNase dose, indicating a trend 
between DNase-induced DNA release and inflammation. However, increased eosinophils were 
not seen in the next lowest dose, despite an increased DNA trend. This suggests that DNA was 
released into BAL, independent of eosinophil inflammation.  
 
6.1.5. Reasoning for dosage decision  
Since no significant difference in dead cell proportions was seen across the different dosage 
groups, the highest dose was used for further experiments to maximise the potential to degrade 
extracellular DNA. 
 
However, it is important to note that the BAL differential count and DNA quantification data 
indicate this may not have been the best choice. Differential counts indicted the 200 µg/ml 
DNase dose alters eosinophil numbers and proportions, and thus the 100 µg/ml dose may have 
been a safer option. However, this finding was observed in female animals, which may explain 
this result. Preliminary data (unpublished) suggested this was not applicable to males. The 200 
µg/ml dose also showed an increase in DNA content in BAL, compared to both the 0 and 50 
µg/ml doses. This DNA release did not appear to correlate with eosinophil infiltration, hence, it 
appears that DNase does not induce inflammation, but unexpectedly lead to more DNA in BAL 
supernatant.  
 
Future studies with DNase-I should involve further safety testing, preferably in animals of the 
same strain, age and gender. It may also be useful to test the source of increased DNA content 
in BAL supernantant. Potentially, known amounts of free DNA could be treated with DNase, to 





















Figure 6.3. DNA content in BAL supernantant for different DNase dosage groups. An increased 
trend was seen for both the 100 and 200 µg/ml DNase dosages. *p<0.05, **p<0.01.  Data is 


























Increased amounts of DNA found with 
increased DNase concentration 
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6.2. IgE/IgG ELISA optimisation  
The ELISA protocol to quantify OVA-specific IgE and IgG antibodies was developed from 
a series of optimisation experiments. Two different methods were considered. These 
methods were based on two strategies, as outlined below. 
 
6.2.1. Capture IgE 
The preferred method involved coating the plate with antibodies specific for IgE, 
removing other OVA specific antibodies that may interfere with detection. Since serum 
concentration of IgE is very low, this method would be preferred. IgE from serum was 
bound to these antibodies, and OVA-specific IgE was then detected using fluorescently 
tagged OVA. This was then detected using an EnSpire multi-plate reader (Perkin Elmer). 
 
To test this method, 50 µl of mouse anti-rat IgE antibody (Bio-rad, MCA193) at 5 µg/ml 
in PBS, was coated onto Maxisorb 96 well (ThermoFisher, 44-2404-21), and left to 
incubate overnight at 4 °C. Following coating, plates were washed with PBS with 0.05% 
Tween-20 (Sigma, P2287-500ML), using a BioTec plate washer (W760). To block 
unspecific binding, plates were incubated with 200 µl of PBS- 1% BSA for one hour at 
room temperature. 
  
Following washing, serial dilutions (same 50 µl volume) of positive and negative control 
samples (serum from a BN rat with confirmed OVA-specific IgE, and serum from a naïve 
BN rat, respectively) were added to the plates, and incubated for 90 minutes at room 
temperature. Both positive and negative samples were provided from a previous study.   
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After incubating and washing, 5 µg/ml or 50 µg/ml of OVA-AF488 (50 µl, Invitogen, 
034781), was added in duplicates. 
 
After a one-hour incubation at room temperature and washing, fluorescently tagged 
OVA was detected at 490 nm using the EnSpire multi-plate reader, before and after 
washing.  
 
Assays were classed as successful if positive controls displayed a higher fluorescent 
signal when compared to negative controls. Ideally, negative controls values would 
display no fluorescence once minused from the blank control.  
 
A successful result was only observed for the highest serum concentration (12.5%) and 
highest OVA-AF488 concentration (50 µg/ml) (Figure 8.4.B.). Due to these findings, the 
method was repeated, with a serum concentration of 20%, and serial dilutions of OVA-
AF488. A differently labelled OVA (OVA-TexasRed, ThermoFisher, 023021) was also 
analysed as a series of dilutions when the method was repeated (Figure 8.4.C and 
8.4.D.). We also included BSA coated plates to detect unspecific binding of OVA. Once 
unspecific binding was subtracted from the detected signal, no consistent difference in 
fluorescent signal was detected between positive and negative serum samples from any 




6.2.2. OVA coated plates 
Since low levels of OVA specific IgE were expected to be present in serum samples which 
may not be detectable using a fluorescence based assay, a second method of detection 
was trialled. In this method, the plates were initially coated with OVA, which will bind 
OVA-specific antibodies from serum. Bound IgE was specifically detected by adding anti-
rat IgE antibody. A secondary antibody, coupled to horseradish peroxidase (HRP) was 
then added, so that bound IgE could be quantified using colour-based absorbance. 
 
To test this method, 5 µg/ml of OVA in PBS, was added to Maxisorb 96 well plates, and 
left to incubate overnight at 4 °C. Following coating, plates were washed with PBS with 
0.05% Tween-20, using a plate washer. To block unspecific binding, plates were 
incubated with 200 µl of PBS- 1% BSA for one hour at room temperature. 
 
Following washing, serial dilutions of positive and negative serum samples were 
incubated for 90 minutes at room temperature. Serum samples were the same as those 
used for the capture IgE method.  
 
Two different dilutions (1:500 or 1:2000 in PBS with 0.1% BSA) of mouse anti-rat IgE 
antibody were then incubated for one hour at room temperature. After washing, plates 
were incubated with sheep anti-mouse-HRP antibody (Amersham Biosciences, NA931) 




After another wash, 50 µl of tetramethylbenzidine (TMB) solution (BUF056A, 170811, 
Bio-Rad) was added to each well. TMB produces a blue colour by donating a hydrogen 
during reduction of H2O2 that is facilitated by HRP. The reaction can be stopped using 
orthophosphoric acid. Absorbance was firstly read prior to stopping the reaction, at 
650nm using the Enspire plate reader. The reaction was then stopped after 30 minutes 
using 50 µl of orthophosphoric acid (1 M). Absorbance was then immediately read at 
450 nm using the Enspire multi-plate reader. For both antibody dilutions, a dose-
dependent increase in signal was observed for positive samples (Figure 6.5.).  
 
To confirm that the signal was specific to OVA specific IgE, this method was repeated to 
include BSA coated control wells. This allowed for background absorbance values to be 
observed. Using this method, a consistent difference, that increased with increasing 
serum concentrations, in positive and negative serum samples were obtained (Figure 
6.5.) 
 
6.2.3. Method choice 
No difference in fluorescence signal was observed between the positive and negative 
samples using the capture IgE method (Figure 6.4.). This likely occurred due to low 
detection of fluorescently tagged OVA. Due to these results, this method was not used 
as the final protocol.  
 
A difference was observed between the positive and negative serum samples when the 
OVA coating method was used (Figure 6.5.). To calculate this difference, replicate values 
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were averaged, and BSA coated blanks used to remove background absorbance. The 
greatest difference was observed with larger serum concentrations (Figure 6.5.C.). Due 
to these findings, the OVA capture method, with a serum dilution of 12.5%, was used 
for IgE quantification.  
 
A likely limitation of using the OVA capture method, involves the low levels of OVA-
specific IgE in comparison to other OVA-specific antibodies. High levels of other OVA-
specific antibodies are likely to interfere with IgE OVA binding sites, due to the low 
proportion of IgE typically present in serum (0.0001-0.001 mg/ml, compared to 0.3-5 
mg/ml for IgG1 (182)). To account for this competition, we also detected OVA specific 
IgG bound to OVA using an anti-rat IgG1 antibody (eBioScience, 108039000). Using this 
method IgG:IgE ratios could be obtained for each sample. IgG is present in serum at high 
levels, and a difference in IgG levels may inaccurately indicate a significant change in IgE 







































Figure 6.4. capture IgE method. Differences between positive and negative serum samples for 
differing capture-IgE optimisation methods. Data is shown as means (n=2).  
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Figure 6.5. OVA coated plates. Differences between positive and negative serum samples for 
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